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ABSTRACT OF THE DISSERTATION
THE DEGRADATION OF PHARMACEUTICAL POLLUTANTS IN
WASTEWATER CATALYZED BY CHLOROPEROXIDASE AND THE
CONSTRUCTION OF CHLOROPEROXIDASE H105R MUTANT
by
Qinghao He
Florida International University, 2016
Miami, Florida
Professor Xiaotang Wang, Major Professor
Trace amounts of pharmaceuticals have been detected in water, from
nanograms per liter to micrograms per liter, and have a negatively effect in the
aquatic environment and an increased potential risk of drug poisoning for human
and animals. In order to address the problem, drug degradation catalyzed by
chloroperoxidase (CPO) has been investigated. CPO is a heme-containing
glycoprotein secreted by the fungus, Caldariomyces fumago, it catalyzes two
major types of oxidations, two one-electron oxidations as catalyzed by most
peroxidases and two-electron oxidations which are rare for conventional
peroxidases.
Five

common

drugs

from

a

variety

of

classes

(acetaminophen,

carbamazepine, sulfamethazine, diclofenac and naproxen) which were persistent
in the environment have been studied. The metabolites of each drug were
identified and the pathways of degradation were proposed. All of them were
found to be 100% degradation efficiency in the CPO-H2O2-Cl- system which the
vii

catalyzation only required low concentration of CPO (normally nanomolar level)
as well as relatively low concentration of H2 O2 as cofactor. This degradation
method is economic and highly efficient, the results of my experiment extensively
support the hypothesis that CPO has a great potential in the environmental
application.
A new mutant of CPO has been constructed to investigate the role of
histidine 105 in the active site of distal pocket. Histidine 105 was suggested to
play an essential role in modulating the chlorination activity by forming hydrogen
bond with glutamic acid 183, histidine has been replaced by arginine to generate
CPO H105R mutant. The construction and transformation were a success but the
protein was expressed as apoenzyme, suggesting the mutagenesis to a larger
arginine residue at position105 disturbed the heme incorporation.
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CHAPTER I.
I. INTRODUCTION
1.1 The occurrence of pharmaceutical pollutants in water
Trace amounts of pharmaceuticals have been detected in water from
nanograms per liter to micrograms per liter. Pharmaceuticals are chemicals that
arise from natural sources or through artificial synthesis with the purpose to treat
disease with highly specific biological targets. Even with lower concentration than
regular contaminants, pharmaceuticals could still target biological organisms
efficiently due to their properties. Pharmaceutical overdose or prolong exposure
increase the potential risk of drug poisoning for both human and animals. Also,
the hazards of pharmaceutical in the aquatic environment have been widely
discussed in recent years. [1, 3]
The annual consumption of prescribed drugs is about 100 tons in Germany,
not including over-the-counter (OTC) drugs, so the actual total should be much
more than the prescribed amounts. The pharmaceutical compounds that enter in
the aquatic environment are mainly from human and veterinary medi cines. The
urine and feces from humans and animals affect the environment by different
pathways. Human pharmaceuticals arise from their excretes and passed into
sewage and are partially removed through the sewage treatment plant (STP)
before entering the surface water that will goes through a series of process
forming the drinking water we intake. Veterinary pharmaceuticals enter the
environment similar to the human route where the animal’s excretes form
contaminate manure which affect the soil and ground water by soil fertilization.
1

Rainfall makes liquid manure and digested sludge flows into surface water. Soil
and ground water may get contaminants from digest sludge applied in STP
treatment. Another contaminated source is the disposal of pharmaceuticals in
domestic waste without any previous treatment, leachates flow from the waste to
landfill site, and continue to ground water and surface water. Finally, these
detectable amount of pharmaceuticals reaches the drinking water sources. (Fig.
1.1).[3, 4]

Figure 1.1 Fate of human and veterinary pharmaceuticals in the
environment. [1, 4]
The trace amouts of pharmaceuticals are not likely to have acute toxicity but
have showed chronic ecotoxicity effects in animals. The lowest observed effect
concentration (LOEC) of diclofenac

on organ

level for rainbow

trout

(Oncorhynchus mykiss) was in the same range as the detected concentration of
the drug in wastewater.[5] The endocrine disrupter drugs have dramatically
negtive effects on aquatic animal such as fathead minnows, with environmentally
relevant concentrations (less than 1 ng/L) of estrogen 17α -ethinylestradiol (EE2),
2

showed adverse effects on fertilization and sex ratio and even secondary sex
characteristics.[6, 7]
The impact of

trace amount drugs in environment cannot be regardless,

antibiotics resistant bacteria were detected in the surface water with highest
average concentration of 78.31 ng/L.[8] Even in low concentration, antibotics can
affect microorganism as signaling hormones, potentially threaten aquatic
ecosystems and the public health[9]
In drinking water, more than 10 drugs were detected frequently, the
concentration of drug could achieve concentration as high as 270 ng/L (clofibric
acid), and the concentration of drug metabolites could reach 0.9 ug/L (AMDOPH
deriving from dimethylaminophenazone). Currently, there is no rountine test for
monitoring the concentration of drug in drinking water. The risk of low
concentrations of pharmaceuticals maybe minor, but with scarce information
about the effects of chronic drug exposure, it still has the potential to affect
human health negatively. The risk assessment of pharmaceutical in aquatic
enviroment still needs to be evaluated in the future.[10-12]
After 2006, the new compounds approved in Europe have to complete the
assessment of enviromental toxicity and fate datasets, the older medicine are still
need to consider of their persistence and harzards.[13]
1.2 The treatment for removal of pharmaceuticals in water
There are two types of wastewater treatment, conventional treatment and
advanced treatment (Table 1.1).

3

Active sludge is the typical treatment of conventional treatment process, the
removal efficiencies were varying regarding different factors such as temperature
of degradation, and hydraulic retention time.[14] The biological filtration including
the STP treatment, a process to remove contaminants in municipal wastewater,
and produce environmental friendly metabolites, has been found to be insufficient
to eliminate all persistent pharmaceutical residues. [15] The removal rates are
inconstant due to the diversity of drug properties, for example, carbamazepine is
resistant in STP but have different removal rate in active sludge.[16]
Advanced treatments are widely investigated in the removing drugs in
wastewater. Ozonation, microfiltration and ultrasound can achieve up to 100%
degradation.

4

Table 1.1 Conventional and advanced wastewater treatment and their removal range efficiency of
pharmaceuticals.

Removal range
(%)

Wastewater treatment
Conventional wastewater treatment

Activated sludge
Biological filtration
Primary settling
Coagulation, filtration and settling
Sand filtration

-193-100a

6-71
3-45
5-36
0-99

Advanced wastewater treatment

Ozonation
Ozonation/ultrasound and sonocatalysis
Ozonation and catalytic ozonation
UV irradiation
Photolysis (UV/hydrogen peroxide)
Dark and light Fenton
UV/TiO2
Biomembrane
Microfiltration and reverse osmosis
Reverse osmosis
Ultrasound

1-100
23-45
>9-100
29
52-100
80-100
>95
23-99
91-100
62-97
24-100

a

The removal efficiency is negative due to the calculation method, the hydraulic retention time is not
considered. The influent sample and effluent sample are not absolutely related. And for
carbamazepine, the negative removal efficiency is consistent, it is suggested the metabolites of
carbamazepine can be converted to parent compound by enzyme activity in STP. [1]

The application of ozonation with H2O2 is used in wastewater recycling for
indirect potable reuse to degrade persistent organic pollutant. [1] However, the
advanced treatments are needed to be further investigated considering the
application possibility to individual pharmaceuticals, for instance, ozonation the
high efficiency normally is activated by relatively high concentration of O 3. The
5

oxidized products might be resistant to the ozonation and contain high acute
toxicity. [17] Different economic and efficient wastewater treatments are required
to be developed considering the complexity of pharmaceutical pollutions.
1.3 The structure of CPO
Chloroperoxidase (CPO) is a heme -containing glycoprotein secreted by the
fungus Caldariomyces fumago. The molecular weight of CPO is approximately
42,000 Daltons. Ferriprotoporphyrin IX is found to be its prosthetic group.[18]
CPO consists of 299 amino acids, the tertiary structure of CPO mainly consists of
eight alpha helical segments and a small beta pair (Fig. 1.2).[19] It has an active
site similar to that of P450s and peroxidase. In comparison with P450s and
peroxidase, the cysteine 29 is the heme ligand of CPO in the proximal pocket
resembling P450s. The polar distal side is similar to peroxidase, whereas the
acid-base catalyst in the active site of CPO responsible for the cleavage of the
peroxide O-O bond is glutamic acid 183, instead of histidine which is typical in
other peroxidase. [20] [21]
There is a narrow channel connected the protein surface to the heme center,
halogen ions are found to bind in the narrow channel, the halogen ion binding
sties found suggested the pathway of halides from the protein surface to heme
active center. In addition, there is a wide channel which suggest to be the binding
site of bulky molecules, reaction such as oxidation, epoxidation might happen
here (Fig 1.3).[21]

6

In conventional heme peroxidases, histidine residue is the acid-base catalyst,
whereas glutamic acid 108 (Glu 183) is the acid-base catalyst of CPO. Generally

Figure 1.2 Crystal structure of CPO was presented by Pymol software, the protein
data bank (PDB; http://www.pdb.org) entry 1CPO was used. Heme prophyrin was
depicted as red color, located in the center of protein. [20]
for heme peroxidase, the catalyst residue interact with another amino acid to
cleave the peroxide bond. In CPO, the residue suggested to interact with Glu183
assisting in the formation of compound I is His105.
In conventional heme peroxidases, histidine residue is the acid-base catalyst,
whereas glutamic acid 108 (Glu 183) is the acid-base catalyst of CPO. Generally
7

for heme peroxidase, the catalyst residue interact with another amino acid to
cleave the peroxide bond. In CPO, the residue suggested to interact with Glu183
assisting in the formation of compound I is histidine105.
His 105 is hydrogen bonded to Glu 183 and Asp 106, the hydrogen bondings
facilites the cleavage of peroxide bond and positioning Glu 183 properly with
relation to heme center during the catalyzation. [20, 21, 23] Two pheylalanine
residues (Phe 103 and Phe 186) are close to the heme iron and thought to
interact with hydrophobic substrate and control the substrate to access the heme
center (Fig 1.4). [21] There is also other result that occurs because of the

Figure 1.3 Slice of CPO crystal structure with sur face presentation. Heme is depicted in magent a,
narrow channel and wide channel are marked by arrow. Yellow sphere presents bromide and
blue sphere presents iodide. The binding sites of halide are labeled by numbers (1 -3) in red color.
[22]

8

modification of histidine residues, suggested His 105 affected epoxidation and
peroxide dismutations but not decreased peroxidation rate.[24] CPO might have
multiply reactive sites regarding the same reaction, and the role of H105 still
needs to be further investigated by other techniques to unravel the mechanism
of CPO.
His 105 is hydrogen bonded to Glu 183 and Asp 106, the hydrogen bondings
facilites the cleavage of peroxide bond and positioning Glu 183 properly within
heme center during the catalyzation. [20, 21, 23] Two pheylalanine residues (Phe
103 and Phe 186) are close to the heme iron and thought to interact with
hydrophobic substrate and control the substrate to access the heme center (Fig
1.4). [21] There is also other result based on the modificatiion of histidine
residues, suggested His 105 affected epoxidation and peroxide dismutations but
not decreased peroxidation rate.[24] CPO might have multiply reactive sites for

Figure 1.4 CPO active site presented by Pymol soft ware (PDB entry 1CPO) with important amino
acids in the distal pocket. Heme is depicted in grey. His 105 was proposed to form hydrogen
bonds with Glu 183 and Asp 106, conferring the proper position of Glu183 and the orientation to
form compound I.Phe 103 and Phe 186 were observed to be close to heme c enter, might control
the access of substrate by polarity. [21]

9

the same reaction, and the role of H105 still needs to be further investigated by
other techniques to unravel the mechanism of CPO.
1.4 The mechanism of CPO catalyzed reactions
The complex structure of the CPO active site associates with the multiple
functions of CPO. The general catalytic cycle of CPO starts from the resting state
of the enzyme, the native ferric center binds by H2O2 at the heme iron and to
form the oxo-ferryl cation radical intermediate called compound I, during the
reaction, two electrons from the heme center are transferred to H2O2 and cleaved
the O-O bond, producing H2 O. Compound I is involved in different types of
chemical reactions. In the dismutation pathway, compound I will continue to react
with H2O2 to generate O2 and H2 O, and be reduced back to its resting state. In
the P450 pathway, the organic substrate (RH) is hydroxylated and compound I is
reduced back to ferric resting state.
Another pathway is peroxidation by forming another reactive intermediate
compound II, the oxo-ferryl intermediate. During the process, one electron from
compound I is transferred to an organic molecule (AH), converting AH to the
radical molecule (A .). [25, 26] Electron is transferred to the organic substrate from
compound II, and CPO returns to the resting state.[27] In general, another major
pathway of compound I is halogenation by interacting with halide (X) to form
compound X, a ferric intermediate. Compound X will halogenate organic
substrate (AH) and generate hydroxyl ion (OH-), returns back to its resting state
(Fig. 1.5).
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Compound I with strong oxidizing ability is also proposed to generate
hypochlorous acid / hypobromous acid, or Cl2 / Br2 as the active intermediates in
the oxidative chlorination. They are presumed to diffuse into the medium and to
oxidize the substrate externally or react with substrates within the active sites.
[28-32] The chlorination mechanism of CPO will be further discussed and
confirmed in my research.
1.5 CPO catalyzed reactions
CPO catalyzes two major types of oxidations; they are two one-electron
oxidations as catalyzed by most peroxidases and two-electron oxidations which
are rare for conventional peroxidases.
1.5.1 One-electron oxidations
The one electron oxidations of CPO include peroxidation and dehalogenation
and polymeration driven by radical. [33, 34] The typical peroxidation of CPO is
the oxidation of 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS), it is
used as ABTS assay to measure the peroxidase activity of CPO / mutant CPO
(Fig 1.6). [35]
Dehalogenation was found in trihalophenols and fluorophenols (Fig 1.7)
According to the general mechanism, fluoride is not involved in halogenation
catalyzed by CPO, whereas in dehalogenation, fluoride of substrate is reacted.
Both reactions show the potential application of CPO in environmental pollutant
treatment. In the defluorination of fluorophenols, dimers and trimers were
generated in one electron oxidation. [33, 34]

The function of polymerization

showed in some other peroxdase is also found in CPO catalyzed reaction. [34, 35]
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Figure 1.5 The general mechanism of CPO catalyzed reation. AH presents the substrate, the oval
presents the heme; compound I and II present the ferryl intermediat es; X presents halogen atom
(except F ).[29]
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Figure 1.6 The oxidation of ABTS catalyzed by CPO.[36]

Dehalogenation was found in trihalophenols (Fig. 1.7)and fluorophenols (Fig
1.8) According to the general mechanism, fluoride is not involved in halogenation
catalyzed by CPO, whereas in dehalogenation fluoride of substrate reacted. Both
reactions show the potential application of CPO in environmental pollutant
treatment. In the defluorination of fluorophenols, dimers and trimers were
generated in one electron oxidation. [33, 34]

The function of polymerization

showed in some other peroxdase is also found in CPO catalyzed reaction. [34, 35]

Figure 1.7 The dehalogenation of trihalophenol catalyzed by CPO.[33]
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Figure 1.8 The mechanism of CPO catalyzed one electron oxidation of fluorophenol.[34]

1.5.2 Two-electron oxidations
The two-electron oxidations includes halogenation and oxygen transfer as the major
reactions. The significant function of CPO was found as the chlorination of
monochlorodimedone (MCD), this reaction is routinely used as MCD assay to measure
the chlorination activity of CPO /mutant CPO (Fig 1.8a).Other halogenation can also be
carried out by bromide or iodide ions.[37] There are other substrates catalyzed by CPO
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in the halogenation, such as phenol. (Fig .1.9), 1,3-cyclopentanedione and alkenes (Fig
1.8b) [37-39] The oxidative chlorination catalyzed by CPO for halogenated phenols or
phenols typically generated different isomers, which will be discussed in my research.
The

other

important

two-electron

oxidation

consists

of

epoxidation

with

enantioselectivity, hydroxylation examples are showed in figure 1.8c [40]
1.6 The application tendency of CPO
The structural and functional features of CPO are suggested its potential as industrial
and environmental biocatalysts, the catalyzation only needs relatively low concentration
H2O2 as cofactor which is economic and safe in application.
To synthesize biological or pharmaceutical chemicals, CPO is an ideal candidate.
The enantioselectivity of oxidation catalyzed by CPO was relatively high regarding the
reaction of oxidizing primary alcohols to the corresponding aldehydes, and result could
be improved with lowered temperature and at fixed pH to achieve a higher enatiomeric
purities (ee). In addition, tert-butyl hydroperoxide was used instead of hydrogen
peroxide.[41]
The fate and mechanism of azo dye degradation catalyzed by CPO was investigated
and the high efficiency of the reaction implied the possibility of CPO application in the
large scale wastewater treatment.[28, 42]
Recently, the degradation of sulfamethoxazole was investigated by utilizing CPO
with active sludge to increase the drug degradation efficiency. [43] The potential of CPO
application in degrading different pharmaceuticals will be analyzed in my dissertation.
To stabilize CPO and increase the recyclability of the enzyme the catalyst was
conjugated to poly (hydroxypropyl methacrylate-co-polyethyleneglycole methacrylate)
membranes, which enhanced the storage and thermal stability compared to the free
CPO. Immobilization of CPO will be one tendency of CPO application, a research will be

15

done to introduce CPO to the large scale application.

Figure 1.9 Reactions catalyzed by CPO in phosphate buffer with chloride ions. (a) The
chlorination of MCD catalyzed by CPO.[38] (b) The examples of halogenation by ,3cyclopentanedione and
alkenes.[38, 39] (c) The typical examples of epoxidation and
hydroxylation catalyzed by CPO with the yields and enatiomeric purities (ee).[41]
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Figure 1. 10 The chlorination of aromatic substrates catalyzed by CPO in phosphate buffer with
chloride ions.[39]
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CHAPTER II.
II. CPO-CATALYZED CHLORINATION AND POLYMERIZATION OF
ACETAMINOPHEN
2.1. Background
Acetaminophen

(N-acetyl-p-aminophenol,

APAP),

also

known

as

paracetamol, is an active ingredient in over-the counter medicines and widely
used for relieving fever and pain. The production of APAP was estimated to be in
the kiloton level in the USA per year.[44] Overdose causes serious liver damage
because of the formation of N-acetyl-p-benzoquinone imine (NAPQI).[45] APAP
is ubiquitous in the natural environment, detected as 1.89 µg/L in ground water
in the U.S.A[46] Occurrence of APAP as a contaminant in wastewater and
drinking water increased the risk of human health and investigations of
biodegradation of APAP.[47, 48]
Bioremediation catalyzed by CPO is a potential treatment as a consequence
of its environmental friendliness and low cost investment. The efficiency of APAP
degradation catalyzed by CPO would be investigated, the metabolites and
pathway would be proposed in this experiment.
2.2 Experimental Procedure
2.2.1 Material
Chloroperoxidase (CPO) is a heme-containing glycoprotein secreted by the
marine fungus Caldariomyces fumago. The isolation of CPO proposed in this
study was a modification of the protocol reported by Morris and Hager[18] where
acetone was used as precipitating agent instead of ethanol as the fractionation
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solvent. CPO with Rz =1.45 (Rz is purity standard defined as A398/A280 = 1.44 for
pure enzyme) was applied in all reactions. All solvents were HPLC grade or
Optima® LC/MS grade, purchased from Thermo Fisher Scientific Inc. (Waltham,
MA, USA). Water was produced by using a Milli-Q® Biocel™ Ultra-Pure water
purification system equipped with 0.22 µM membrane filter cartridge (EMD
Millipore, Billerica, MA, USA), and an organic removal cartridge (Evoqua Water
Technologies, Lowell, MA, USA).
2.2.2 UV-Visible spectrophotometry
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the
UV spectra of the degradation products. The drug solution was scanned by
dissolving 0.11 mM APAP in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75.
The same solution was monitored after mixed with 0.55mM H2 O2. The reaction
was initiated with the addition of 5 nM CPO and UV-Vis spectrum was recorded
for the reaction time: 1 minute, 2.5 minutes, and 4 minutes.
2.2.3 Liquid chromatography and mass spectrometry
2.2.3.1 Sample preparation
To investigate the degradation efficiency, 62.56 µM APAP was reacted with
321.56 µM H2O2 and 0.43 nM CPO for 1 hour at room temperature. Mixture was
centrifuged at 3,000 g in Centriprep® centrifugal filter unit with a 30,000 Dalton
cut-off membrane (EMD Millipore, Billerica, MA, USA). The yielded products was
collected after centrifuged for 1min. Ethyl acetate was used to extract the filtrate
while shaking vigorously, and the supernatant was evaporated to dryness by
using nitrogen gas. The dried metabolites were dissolved in H2 O /methanol (95:5
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v/v) to make the final concentration 1 mg/L (ppm). Sample was stored at -20 °C
in a freezer or immediately run in the LC-Q-TOF-MS mass spectrometer system.
A low concentration of CPO and H2 O2 reaction sample was prepared as
follows: 6.86 µM H2 O2 was added directly to Centriprep® centrifugal filter unit with
the same membrane size as described above.

Then 66.20 µM APAP were

added, catalyzed by the addition of 1.28 nM CPO in the 100 mM phosphate
buffer with 20 mM KCl for 3 minutes and 5 minutes. The experiments were run in
triplicate. The dried metabolites were dissolved in H2O/methanol (95:5 v/v) to
make an approximate concentration of 1 mg/L (ppm), and detected by LC-QTOF-MS system immediately.
The high concentration of APAP sample was prepared by mixing 413 µM
APAP with 2 mM H2 O2, catalyzed by 2 nM CPO for 35 minutes at room
temperature. The extraction was carried out by ethyl acetate, and the organic
layer was dried by nitrogen gas. Metabolites were dissolved in 1.5 mL
H2O/methanol (95:5 v/v) to make an approximate final concentration of 5 mg/L
(ppm). The sample was filtrated through 0.22 µM polyethersulfone syringe filter.
The sample was stored in a freezer at -20°C, detected both in Q-TOF-LC-MS
system and Triple-quadrupole LC-MS/MS system.
2.2.3.2 Instrumentation and chromatographic separation
The Agilent 1290 Infinity UPLC system coupled with Agilent 6530 Q-TOF
mass spectrometer was

used for the chromatographic separation and

identification of the metabolites. The Agilent MassHunter Data Acquisition
Software (rev. B0.06.00) was used to control the UPLC and the mass
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spectrometer. Mass Hunter Qualitative Data Analysis Software (Rev. B.07.00 was
used for data mining and identification. An Agilent ZORBAX Eclipse plus C18
Rapid Resolution High Definition (RRHD) column (100 mm×1.8 µm) was applied,
the column temperature was set at 30 °C via a thermostatted column
compartment (TCC). An infinity 1290 automatic injector was used to Inject 1 µL
(microliter) of the sample to the column. A flow rate of 0.4 mL/min was used and
a aqueous mobile phase A consisting of water with 5 mM ammonium formate
with 0.1% formic acid and the organic mobile phase B consisting of acetonitrile
with 0.1% formic acid. The optimized chromatographic gradient was at 0 minute,
95% A and 5% B and B increased linearly to 95% over 8 minutes, this gradient
was maintained for 1 minute. The positive ionization mode was applied during all
experiments.
In full scan MS mode, the accurate mass data of the molecular ions were
processed through the Agilent MassHunter Qualitative Analysis software. The
collected retention times and confirmed formulas of every metabolite were
applied in targeted MS/MS mode to identify metabolites information.
Additionally an Agilent 6460 Triple-Quadrupole LC/MS/MS mass spectrometer
was used to increase the detection sensitivity of the isolated metabolites that
were initially identified by the LC-QTOF mass spectrometer. The same column
and elution program previously used in the LC-QTOF was employed in the LCQQQ-MS system.
2.2.3.3. Data Mining and Database development.
To create a database of all metabolites with optimized parameters, several
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search algorithms were used in Mass Hunter Qualitative Data Analysis Software.
One of this algorithms was Find by Formula (FbF) which allow the search of a
compound using its molecular formula. The search could include not only the
formation of the molecular ion [M+H]+ but also the formation of adducts (like
ammonium or sodium adducts) typically observed under the ionization conditions
in electrospray. The samples were initially infused into the system by flow
injection analysis (FIA) and later subjected to chromatography. Additional work
was performed by LC-QQQ-MS detection for those metabolites present at low
levels of concentration.
2.3 Result and discussion
2.3.1 UV-Vis study of CPO-catalyzed degradation of APAP

Figure 2.1 UV -Vis Spectra of APAP , APAP with H2O2 and its metabolites at 1min, 2.5min,
and 4min.

The UV-Vis Spectrum of APAP (0.11 mM) were scanned in 100 mM KH2PO4
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buffer with 20 mM KCl at pH 2.75. The Spectrum of APAP showed a strong
absorption at 242 nm. After mixed with 0.55 mM H2 O2, the absorption curve
increased slightly due to absorbance of H2O2. 1 minute after addition of 5 nM
CPO, the 477 nm absorption decreased, and increased at 4 min. The absorption
at 218 increased after 1 min, and stopped increasing at 2.5 min (Fig. 2.1). The
absorption of metabolites covered the absorption of original drug, which made
the detection of kinetic parameter of APAP degradation catalyzed by CPO
impossible.
The same reaction was carried out under the same condition except for the
absence of chloride ion (KCl) in phosphate buffer. Without KCl, the absorbance
did not change after the addition of CPO. Chlorine ion is necessary in the
degradation of APAP in CPO-H2O2-Cl- system.
2.3.2 LC-Q-TOF- MS
To investigate the degradation efficiency of APAP in CPO-H2O2 -Cl- system,
62.56 µM APAP was reacted with H2O2 (321.56 µM) and CPO (0.43 nM) for 1
hour, the sample was analyzed by LC-Q-TOF-MS, APAP was not observed, the
degradation efficiency by low concentration of CPO could achieved 100%,
suggesting the potential of the application of CPO in large-scale waste water
treatment.
There were 7 APAP metabolites (coded from AM1 to AM7) confirmed by
different retention times and accurate mass-to-charge ratios (m/z). The elemental
formula, retention time, the relative mass difference between the observed mass
and the mass of the target compound (in parts per million), and the difference
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between the observed mass and the mass of target compound (in milliDaltons)
were collected (Table 2.1).
Table 2.1 Accurat e-Mass LC-Q-TOF-MS data for the identification of APAP and its
metabolites.

The mass spectrum of each individual metabolite found (7 in total) are
included in Appendix I. The mass accuracy of the standard drug (APAP) was
calculated and the values ranged between 0.37 ppm and 9.75 ppm. The relative
mass differences of metabolites were between 0.59 ppm and 3.23ppm. The
mass differences of all compounds were less than 1.1 mDa. This method was
proved to be efficient for determination of the metabolites of APAP.
Dimer (AM2) and Trimer (AM6) were formed, their chlorinated products were
observed as AM3, AM7 respectively. For chlorinated metabolites, the isotope
peaks were detected as the conformation of addition of chlorine atom. For AM1,
AM3 and AM7, the two major peaks of each spectra separated by 2 m/z units
and peak heights are in the ratio of 3:1, proved these molecules contain one
chlorine atom. For AM4 and AM5, there were 3 lines in the molecular ion region
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(M+, M+2 and M+4) with gaps of 2 m/z units between them, and with peak
heights in the ratio of 9:6:1, it was confirmed that both compounds contain 2
chlorines.
The structures of each metabolite were confirmed in targeted MS/MS by
retention time and fragment ions (Fig. 2.2). The concentration of AM7 was low,
the majority form of AM7 was [M+Na]+ (472.1453 m/z).
2.3.3 Triple-quadruple LC/MS/MS
Agilent Technologies 6460 Triple-quadrupole LC/MS/MS in multiply reaction
monitoring (MRM) mode was applied in investigation of metabolites of APAP.
Data were analyzed with Agilent MassHunter Qualitative Analysis software. After
the formula of metabolites was confirmed by LC-Q-TOF-MS,
Individual metabolites were assessed with a more sensitive analytical technique
(LCQQQ-MS). For example, AM1 showed one solid peak with a mass
corresponding to m/z 186.03 in Q-TOF both in full scan mode. The use of an
MRM method in Triple-quadrupole LC/MS/MS, two peaks were clearly eluted at
different retention times. For detection of isomers in complex biological matrix,
Triple-quadrupole

shows

excellent

sensitivity

and

selectivity

for

target

compounds by filtering out the purities with the same molecular weight as
targeted products.
The specific parameters, including optimized fragmentor voltage and collision
energy (CE) for different MRM transition has been determined by flow injection
analysis without column (FIA) with MassHunter Optimizer software (Appendix II).
Routine MRM mode, more than one MRM transition per compound is used to
25

avoid false-positive results, two transitions are monitored for one compound in
most cases.
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C8H9NO2 (APAP)

C8H8ClNO2 (AM1)

C16H16N2O4 (AM2)

C16H15ClN2O4 (AM3)

C8H7Cl2NO2 (AM4)

C16H14Cl2N2O4 (AM5)

C24H23N3O6 (AM6)

C24H22ClN3O6 (AM7)

Figure 2.2 The targeted MS/MS spectra of APAP and its metabolites.
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The relative area in chromatogram was used to measure the abundance of
each metabolite (Fig. 2.3a). AM1 and AM2 were the major product. To investigate
the mechanism of the degradation, limited concentration of H2O2 was added to
the reaction, the ratio of APAP and H2O2 was 10:1. At first 3 minutes, the
formation of AM2 was predominant within 5 minutes. The proportional area was
consistent with the degradation by higher concentration H2O2. (Fig. 2.3b). There
were no other metabolites observed at the first reaction stage, suggesting the
mechanism that AM3, AM4, AM5, AM6 and AM7 were formed from AM1 and AM2
(Figd2.4).
7E+04

125%

AM1

Relative Area

AM2
5E+04

75%

Area

Relative Area

100%

50%

4E+04

2E+04

25%

0%
AM1 AM2 AM3 AM4 AM5 AM6 AM7

Code of Metabolites

0E+00

3min

5min

Time

Figure 2.3 The relative area of each metabolite. (a) In high concent rated sample, the area of
AM1 was set as 100%, compared with AM1, AM2 -AM6 is 96.94%, 48.08%, 18.12%, 8.93%,
respectively. The area of AM7 was only 0.06%. (b) The area of AM1 at 3min was 5602 with
error is 4879, at 5min increases dramatically to 50800 with error 2103; AM2 is 63866 at
3min with error 1452, and 57423 at 5min with error 1201 .Each ex periment was run in
triplicate.

The different elution times of the same formula was considered as isomers. In
addition, the exist of isomers could also be suggested with distinctive product
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ions by the same fragmentor voltage at different retention time (Table 2.2). The
concentration of AM7 is too low to detect the different elution time of isomers.
The other 6 metabolites showed a good resolution.
To consider the relatively low concentration isomers, all optimized MRM
transitions were loaded into the MassHunter Acquisition software for performing
data analysis. The chromatograph of each formula was extracted by Agilent
MassHunter Qualitative Analysis software with the proposed structures, the first
structure shown on the chromatogram is the proposed primary structure with
highest concentration (Fig 2.5.)
Table 2.2 Information of the proposed isomers (RT presents retention time).
Code

RT (min)

Area

Share transitions

Specific transitions

AM1-1

4.220

517761

AM1-2

3.923

34544

AM2-1

3.664

812260

AM2-2

4.292

64986

AM3-1

4.405

223747

AM3-2

4.890

66386

AM3-3

9.397

111378

AM4-1

5.090

77208

AM4-2

4.776

4866

AM5-1

5.423

375540

218, 326

AM5-2

5.704

104506

218,326

AM5-3

4.943

71328

326

AM5-4

5.551

54057

326

AM6-1

9.714

36531

191, 253, 433

AM6-2

9.046

5142

AM6-3

8.480

5122

AM6-4

8.838

2809

43,54, 73,81, 82, 109, 168

53, 80, 144

43, 127, 154 , 172, 182, 200, 217

108, 259, 283

142, 170, 198, 199,215, 257, 293,317
43

124, 142, 199, 293, 317

43, 52, 79, 143, 178

71

57

71
71
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Figure 2.4 The proposed mechanism of the degradation of APAP catalyzed by CPO
present by primary structure of each metabolites.
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Figure 2.5 Extracted chromatogram of APAP and its metabolites detected by Triple-Quadrupole LC/MS/MS.
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Figure 2.5 (Cont.) Extracted chromatogram of APAP and its metabolites detected by Triple-Quadrupole LC/MS/MS.

2.4 Discussion
NAPQI is the significant hepatotoxicity intermediate product of APAP
catalyzed by the cytochrome P450 enzyme.[49] CPO shares the similar structure
of P450 in proximal heme iron thiolate ligand,[50] but obviously, for catalyzing the
degradation of APAP, the function of chlorination and dimerization is preferred
instead of oxidation. For degradation of APAP, CPO-H2O2 -Cl- system works
differently from hypochlorite and P450, suggesting the specific ability of
detoxification of APAP. AM1 is a chlorinated APAP product, previously AM1-1 was
reported in nitration processes of acetaminophen in nitrifying activated sludge as
a low concentration transformation product. [51]
AM1-1 and AM4-1 are two ring chlorination metabolites of APAP. They were
detected after APAP (10 µmol/L) reacted with hypochlorite (57 µmol/L) for 1 hour,
88% APAP was transformed. The approximate concentration of two chlorinated
metabolites was 7% of the initial APAP. The concentration was relatively low
when compared with the experiment catalyzed by CPO. When APAP mixed with
hypochlorite, two toxic quinoidal oxidation products were produced, 1,4benzoquinone and N-acetyl-p-benzoquinone imine (NAPQI) accounted for 25%
and 1.5% of the initial acetaminophen concentration, respectively, which were not
detected in CPO-H2O2 -Cl- system. Evaluation on the toxicity of the final products
indicated that, CPO has the potential application in the purification of waste water
when compared with regular chlorine disinfection systems.
AM4 was two electron-withdrawing chlorine substituent, compared the LDH
leakage in hepatocytes with APAP, the LDH leakage was 36%, and APAP was
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about 51%. Other analogues at the 3,5 positions were tested (R=-F, -Br, and -I),
the value were from 42% to 15%. Besides, these halogenated products
decreased the inhibitory potency towards cyclooxygenase, showed the deceased
function of drug, both evidences implied that the halogenation of APAP in waste
water by CPO-H2O2 -Cl- system could decrease the cytotoxicity and drug effect in
human body.[49]
Dimer (AM2), trimer (AM6) and their chlorinated products (AM3, AM5, and
AM7) were identified in CPO catalyzed reaction. Both dimer and trimer were
detected in the horseradish peroxidase catalyzed polymerization of APAP, there
were two dimers and three trimers detected by 500-MHz proton magnetic
resonance spectroscopy.[35] The number of polymerized isomers generated by
CPO catalyzed reaction were consistent with horseradish peroxidase catalyzed
polymerization, and we proposed the same structure of each isomers. In the
polymerization by horseradish peroxidase, the polymers formed primarily through
a covalent bond between carbons ortho to the hydroxyl group due to the high
unpaired electron density, and to a lesser extent, between the carbon ortho to the
hydroxyl group and the amino group of another APAP molecule, as the isomer
ratios observed from chromatograms of CPO catalyzed reaction.
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CHAPTER III.
III. CPO-CATALYZED DEGRADATION OF CARBAMAZEPINE
3.1 Background
Carbamazepine (CBZ) is widely used in the treatment of epilepsy, trigeminal
neuralgia and bipolar disorder. [52] CBZ has been studied as persistent
anthropogenic pollutant which is detectable in surface water, ground water, and
even in drinking water. In Germany, the annual consumption of CBZ was over 80
tons, and the concentrations detected were 6.3 µg/L in STP effluent, 26 ng/L in
urban groundwater, 762 ng/L in surface water, 1640 ng/L in raw sewage, and 6586 ng/L in tap water.[4, 7, 53] In other European surface water, the highest
concentration was reported from 110-800 ng/L. [1] In addition, 420 ng/L CBZ was
detected in the ground water used for public drinking water supply in USA. [46]
10 µg/L CBZ showed obviously cytotoxic to gill cell of fish.[54] It was reported
that CBZ administration caused tumors in rats for 2 years drug treatment, and
reduced the humoral and cellular immune responses, and induced spleen
cellularity.[55, 56] Therefore, Long time exposure to CBZ in drinking water is a
potential risk to human health.
The common water treatment is effective to degrade CBZ, even with some
new biodegradation method was investigated such as biodegradation by algea,
fungus, phtocatalysis, etc. [4, 57-59] CPO has the potential to apply in
degradation of CBZ due to its high efficiency (catalyzed within minutes), less
expensive (work with nanomolar level enzyme) and its stability in acidic
wastewater (pH 2.0-5.0). The CBZ degradation efficiency in water, the kinetic
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parameters and the products of CBZ catalyzed by CPO was investigated in this
experiment.
The aim of this experiment was to investigate the potential application of CPO
in the degradation of CBZ. The efficiency of CPO in the degradation of CBZ was
measured. The operating conditions including the concentration of Cl-, reaction
buffer pH, and the concentration of H2O2 was optimized, and under the optimized
conditions, the enzyme kinetic and degradation pathway was studied.
3.2 Experimental Procedure
3.2.1 Material
All material and chemicals used were the same as described in section 2.2.1.
3.2.2 UV-Visible spectrophotometry
3.2.2.1 UV-Vis spectrum of degradation
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the
UV spectra of the degradation products. The drug solution was scanned by
dissolving 0.07 mM CBZ in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75.
The same solution was monitored after mixed with0.35mM H2O2 . UV spectra
were recorded after the addition of 5 nM CPO for 1minute, 2.5 minutes and 4
minutes. The degradation efficiency was calculated according to Equation (1)
Efficiency (%) =

𝐴 0 −𝐴 𝑡
𝐴0

× 100

(1)

3.2.2.2 Effect of diverse parameters on CPO degradation
The effect of the concentration of chloride was investigated. Degradation was
carried out in 100 mM phosphate buffer at pH 3.0 with 0.07 mM CBZ and 0.07
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mM H2 O2, concentration of chloride was increased from 0 to 20 mM, 285 nm
wavelength was monitored immediately after 2.5 nM CPO was added.
The degradation rate at pH range of 2.0 to 5.0 was investigated to probe the
effect of pH on CPO catalyzed reaction. The reaction was carried out in 100 mM
phosphate buffer with 20 mM KCl, 0.07 mM CBZ, and 0.07 mM H2O2 . H3PO4 and
KOH were used to adjust pH, 285 nm wavelength was monitored immediately
after

the addition of 2.5 nM CPO. The calculated time was from 0.2 to 0.4

minute.
The degradation rate of CBZ was determined by different concentration of
hydrogen peroxide from 0.07-0.71 mM in 100 mM phosphate buffer with 20 mM
KCl and 0.07 mM CBZ at pH 3.0. 285 nm wavelenth was monitored immediately
after the addition of 5 nM CPO. Rate from 0.1mintute to 03 minute was
calculated as degradation rate.
It was assumed that the degradation would follow Michaelis-Menten kinetics,
and the Lineweaver-Burk plot Equation was used to calculate Michaelis-Menten
constant (K m) and maximum reaction rate (V max ) (2), where the [𝑆] presents the
concentration of substrate (CBZ), V presents the initial reaction rate, the rate was
calculated by monitoring at 285 nm absorbance from 0.1-0.2 minute. The
reaction was carried out in 100 mM concentration of KH2PO4 buffer with 20 mM
KCl at pH 2.75, the concentration of CBZ was varying from 0.02 mM to 0.11 mM.
UV was started to monitor immediately after adding 0.35 mM H2O2.
1
𝑉

=

𝐾𝑚
𝑉𝑚𝑎𝑥

1

1

𝑆

𝑉𝑚𝑎𝑥

×[ ]+

(2)
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The turnover number (kcat) was obtained by the equation (3), calculated from the
maximum reaction rate (Vmax ) and the concentration of CPO (E0).

𝑉𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡 [ 𝐸0 ]

(3)

All experiments were triplicated and data reported were mean values of three
independent measurements with standard deviation.
3.2.3 Liquid chromatography and mass spectroscopy
3.2.3.1 Sample preparation
To investigate the degradation efficiency, CBZ was dissolved in methanol to
make stock solution (21.19 mM), 10.59 µM (2.5 mg/L) CBZ was reacted with
107.19 µM H2O2 and 2.9 nM CPO for 10 minutes at room temperature. Mixture
was centrifuged at 3,000 g in Centriprep® centrifugal filter unit with 30,000 Dalton
cut-off membrane (EMD Millipore, Billerica, MA, USA). The filtrate was collected
after centrifuged for 1min. Ethyl acetate was used to extract the filtrate while
shaking vigorously. The remove the organic solvent, nitrogen gas purge was
applied to dry the sample. The dried residues were dissolved in H2O /methanol
(95:5 v/v) to make the final concentration approximate 1 mg/L (ppm). The sample
was stored at -20 ℃ in a freezer, or immediately run in LC-Q-TOF-MS mass
spectrometer system.
To detect all metabolites of CBZ, CBZ was dissolved in methanol to make
stock solution (21.19 mM), a high concentration of CBZ sample was prepared by
mixing 62.56 µM (14.8 mg/L) CBZ with 0.4 nM CPO, H2 O2 stock solution (41.16
mM) was added to reaction system at 56.5 µL/minute to make the final
38

concentration of H2 O2 up to 316.56 µM. The total reaction time was 55 minutes.
The solution was extracted by ethyl acetate, and the supernatant was evaporated
by using nitrogen gas. Metabolites were dissolved in 2.0 mL H2O/methanol (95:5
v/v) to make the final concentration approximately 5 mg/mL (ppm). The sample
was centrifuge at 1200 g for 10 minutes, 1.5 mL supernatant was removed by
syringe. Filtration was applied by using 0.22 µM polyethersulfone syringe filter.
The sample was stored at -20 ℃ in freezer, detected both in LC-Q-TOF/MS
system and Triple-Quadrupole LC/MS/MS system.
To investigate the mechanism of degradation, samples were prepared with
low concentration of H2 O2. 6.86 µM H2O2 was added directly to Centriprep®
centrifugal filter unit (30,000 Dalton) with 42.28 µM CBZ, catalyzed by 1.3 nM
CPO in the 100 mM phosphate buffer with 20 mM KCl for 1 minute, 3 minutes
and 5 minutes, filter units were centrifuged at 3000g for 1min at room
temperature, and extracted the filtrate by ethyl acetate, purged the organic phase
with nitrogen gas to dryness. The dried metabolites were dissolved in
H2O/methanol (95:5 v/v) to make the final concentration approximate 1 mg/L
(ppm), and detected by LC-Q-TOF-MS system immediately. Experiments were
run in duplicate.
3.2.3.2 Instrumentation and chromatographic separation
The instrumentation and chromatographic separation were the same as in
section 2.2.3.2.
3.2.3.3. Data Mining and Database development
The data Mining and Database development were the same as in section
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2.2.3.3.
3.3 Result and discussion
3.3.1

UV-Vis

study

of

CPO-catalyzed

degradation

of

carbamazepine

Figure 3.1 UV-Vis Spectra of CBZ with H2O2 and its metabolites at 1min, 2.5min and 4min.

UV-Vis Spectra of CBZ (0.07 mM / 16.53 mg/L) and H2O2 (0.75 mM) were
scanned in 100 mM KH2PO4 buffer, 20 mM KCl at pH 2.75 (Fig.3.1). The
Spectrum of CBZ showed a strong absorption at 285 nm. 1 minute after addition
of 5 nM CPO, the 285 nm absorption decreased, and stopped increasing at 4
minutes (Fig. 3.1). Wavelength at 285 nm was used to measure kinetic
parameter of CBZ degradation catalyzed by CPO.
The same reaction was carried out under the same condition except for the
chlorine ion (KCl) in phosphate buffer. Without KCl, the absorbance did not
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change after the addition of CPO. Chlorine ion is necessary in the degradation of
CBZ in CPO-H2O2-Cl- system.
According to Equation (1), The efficiency of degradation catalyze by 5 nM
CPO was 96% within 4 minutes, the efficiency might be more than 96% since the
the tail of the UV peak of product seemed cover the original drug (285 nm).
3.3.2 The effect of chloride on the degradation of CBZ
Degradation rate was calculated from 0.2-0.6 minute. The degradation rate
increased from 0 to 18.89 µM/min. The obsevation was consistent as described
in section 3.2.1, suggested that chloride participates in the degradation of CBZ.
(Fig. 3.2).
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Figure 3.2. The effect of chloride on the degradation of CB Z. Data were collected from
triplicate experiment in 100 mM phosphate buffer at pH 3.0, with 0. 07 mM CB Z, 0.07 mM
H2O2, and 2.5 nM CPO.
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3.3.3 The effect of pH on the degradation of CBZ

Figure 3.3 The effect of pH on CB Z degradation. Data were collected from triplicate
experiment in 100 mM phosphate buffer (20 mM KCl) with 0.07 mM CBZ, 0.07 mM H 2O2,
and 2.5 nM CPO at pH 3.0.

The optimum pH for the degradation of CBZ is 3.0 in the presence of 20 mM
Cl-, the degradation efficiency decreased from pH 3.5 to 5. This curve was close
to the expected chlorination reaction and oxidation reaction, [60] suggested CPO
could be applied in the acid wastewater treatment. (Fig. 3.3).
3.3.4 The effect of H2O2 concentration
The degration rate was increased as the concentration of H2 O2 increased to
0.53 mM. From 0.53 to 0.71 mM, the rate was still stable, only decreased
slightly.This could be due to the degradation of CPO by the high concentration of
H2O2.[61] The stability of CPO in the presence of H2O2 compared with other
peroxidase is suggested that CPO has a better prospect of application than the
same class enzyme. (Fig. 3.4).
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Figure 3.4 The effect of H2O2 concentration, Data were collected from triplicate
experiment in 100 mM phosphate buffer (20 mM K Cl) with 0. 07 mM CB Z and 5 nM CPO
at pH 3.0.

3.3.5 The kinetic parameters of CBZ degradation catalyzed by CPO

Figure 3.5 The effect of CB Z concent ration. Data were collected from triplicate
experiment in 100 mM phosphate buffer (20 mM KCl) with 0.07 mM H2O2, and 5 nM
CPO at pH 3.0, concentration of CBZ was varied from 0.02 mM to 0.11 mM.

Different concentrations of CBZ were reacted with 0.07 mM H2 O2 with 5 nM
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CPO (Fig. 3.5). According to Equation 2, the kinetic parameters of CBZ
degradation catalyzed by CPO was calculated (Table 3.1)
Table 3.1 The kinetic parameters of CBZ degradation catalyzed CPO.

Km

Vmax
-1

kcat

kcat/Km

-1

-1 -1

(µM)

(µM s )

(s )

(µM s )

73.35

3.87

733

10.54

R2

0.9995

3.3.6 LC-Q-TOF- MS
To investigate the degradation efficiency of CBZ in CPO-H2O2 -Cl- system,
10.59 µM CBZ was reacted with 107.19 µM of H2O2 and CPO (2.9 nM) for 10
minutes, the sample was analyzed by LC-Q-TOF-MS, CBZ was not observed,
the degradation efficiency by low concentration of CPO could achieved 100%,
suggesting the potential of the application of CPO in large-scale waste water
treatment.
Samples were detected in Agilent Technologies 6530 Accurate-Mass LC-QTOF-MS in full scan MS mode, the accurate mass data of the molecular ions
were processed through the Agilent MassHunter Qualitative Analysis software.
There were 15 CBZ metabolites (coded from CM1 to CM15) confirmed by
different retention times and accurate mass-to-charge ratios (m/z). The elemental
formula, retention time, the relative mass difference between the observed mass
and the mass of the target compound (in parts per million), and the difference
between the observed mass and the mass of target compound (in milliDaltons)
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were collected (Table 3.2).
Table 3.2 Accurate-Mass LC-Q-TOF-MS data for the identification of CBZ and its
metabolites.

Code

Formula

Retention time Experimental mass Theoretical mass

Diff

Diff

(min)

(m/z)

(m/z)

(ppm)

(mDa)

CMZ

C15H12N2O

5.901

236.0943

236.0950

-2.73

-0.64

CM1

C15H12N2O2

4.314

252.0914

252.0899

6.21

1.56

CM2

C15H14N2O3

3.366

270.1004

270.1004

-0.08

-0.02

CM3

C14H11NO2

2.839

225.0790

225.0790

-0.06

-0.01

CM4

C14H9NO

6.776

207.0680

207.0684

-1.84

-0.38

CM5

C13H9N

3.970

179.0728

179.0735

-4.12

-0.74

CM6

C13H9NO

5.185

195.0678

195.0684

-3.23

-0.63

CM7

C15H13NO2

3.793

239.0938

239.0946

-3.64

-0.87

CM8

C14H9NO2

2.379

223.0630

223.0633

-1.64

-0.37

CM9

C15H11NO3

3.959

253.0748

253.0739

3.53

0.89

CM10

C16H14N2O2

4.863

266.1058

266.1055

0.88

0.23

CM11

C15H12ClNO2

6.061

273.0559

273.0557

0.90

0.25

CM12

C14H8ClN O

7.985

241.0298

241.0294

1.36

0.33

CM13

C13H8ClN

7.442

213.0356

213.0345

5.14

1.10

CM14

C13H8ClNO

6.222

229.0291

229.0294

-1.48

-0.34

CM15

C14H8ClNO2

3.111

257.0240

257.0244

-1.46

-0.38

All the relative mass difference of the standard drug (CBZ) and metabolites
were less than 5.0 ppm except for CM1 (6.21 ppm) and CM13 (5.14 ppm).The
relative mass difference of metabolite CM1 and CM13 in all experiments were
between 0.19 ppm and 9.54 ppm, 0.74 ppm and 5.14 ppm, respectively. The
mass differences of all compounds were less than 2.0 mDa. This method was
proved to be efficient for determination of the metabolites of CBZ.
The mass spectra of each individual metabolite were collected in positive
mode by MassHunter Workstation software (Appendix I). Since it was in positive
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mode, all the compounds were detected as molecular ion [M + H]+ except for
CM9, the detected molecular ion was [M + NH4 ] + adduct (271.1085 m/z), the
ammonium adduct formation was favored in the ion source probable due to the
ion pairing effect on the functional group responsible of ionization.
For chlorinated metabolites, the isotope peaks were detected as the
conformation of addition of chlorine atom, the two major peaks of each spectra
separated by 2 m/z units and peak heights are in the ratio of 3:1, proved these
molecules contain one chlorine atom.
The structures of each metabolite were confirmed in targeted MS/MS by
retention time and fragment ions (Fig. 3.6). There were 2 types of metabolites
based on their structure. The first type contained CM1, CM2, CM9, CM10 were
suggestive of oxygen insertion into the CBZ-based structure. The other structures
were the second type, structures were based on acridine (CM5), the
decarbonylation product of parent compound. All chlorinated metabolites were
from acridine-based structures. CM11, CM12, CM13, CM14, CM15 was the
chlorinated product of CM7, CM4, CM5, CM6, CM8, respectively. CM7 was
generated from CM3 by methylation of hydroxyl group. CM8 was the
hydroxylated product of CM4.

47

C15H12N2O (CBZ)

C15H12N2O2 (CM1)

C15H14N2O3 (CM2)

C14H11NO2 (CM3)

C14H9NO (CM4)

C13H9N (CM5)

C13H9NO (CM6)

C15H13NO2 (CM7)

Figure 3.6 The targeted MS/MS spectra of CBZ and its metabolites.

48

C14H9NO2 (CM8)

C15H11NO3 (CM9)

C16H14N2O2 (CM10)

C15H12ClNO2 (CM11)

C14H8ClNO (CM12)

C13H8ClN (CM13)

C13H8ClNO (CM14)

C14H8ClNO2 (CM15)

Figure 3.6 (Cont.).The targeted MS/MS spectra of CBZ and its metabolites .
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The concentrations of all metabolites were measured as compound area by
MassHunter Workstation software, and presented by percentage of all
compounds as pie chart, all chlorinated compounds were showed in the second
pie chart at right side (Fig. 3.7)

Figure 3.7. The percentage of each metabolites measured by compound area.
Metabolites shared the same structure presented by the same color.

To investigate the mechanism of degradation process, the experiment was
carried out for limited reaction time (1,3 and 5 minutes) with low concentration of
H2O2 (6.86 µM), the ratio of the concentration of CBZ and H2O2 was about 7:1.
Only part of CBZ was degraded, and only several metabolites were detected
which could be suggested as the first formed metabolites (Fig 3.8). At the first
minute, only CM1, CM2, CM9, CM10 were formed, the four proposed structures
were suggestive of oxygen insertion into the CBZ-based structure, produced
directly from CBZ without decarbonylation, CM1 was the most abundant
metabolite, suggested the first step of degradation was the epoxidation of CBZ.
The percentage of these four compounds decreased significantly after reacted
with higher concentration of H2 O2 for longer time (Fig. 3.7). From 3 minutes,
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acridine (CM5) was formed, CM7 and CM8, two acridine-based metabolites were
detected at 5 minutes. The final concentrations of them were the relatively high.
Compared with the CBZ-based structure compounds, acridine-based structure
were suggested as the major products, acridine (CM5), the decarbonylation
product of parent compound, with CM6, CM7 and CM8 were the major
metabolites of the degradation catalyzed by CPO, CBZ-based structures existed
as intermediates of the degradation. CM5, CM6, CM7 and CM8 were the most
abundant metabolites, suggested they were the major metabolites of the
degradation catalyzed by CPO.

Figure 3.8 The area of metabolites with limit ed H2O2 at 1 min, 3 min and 5 min detected
by Accurate-Mass LC-Q-TOF-MS. All experiments were duplicates and dat a reported
were mean values of two independent measurements.

The chlorinated products were observed as CM11-CM15, the concentration of
them were relatively low (Fig. 3.7) and they were not observed at the first stage
of reaction (Fig. 3.8), these metabolites were not the major product of the
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degradation catalyzed by CPO.
The chromatograms of CBZ and its metabolites were collected with their
proposed structures (Fig. 3.9). In the chromatograms of CM1, CM2, CM9, CM11,
CM12, CM13, CM14 and CM15, there were isomers identified by different
retention time. For CM1, CM9, CM11 and CM12, metabolites had problem of
signal to noise ratio might due to the low concentration, chromatograms of the
four compounds were collected by Agilent Technologies 6460 Triple-quadrupole
LC/MS/MS in multiply reaction monitoring (MRM) mode.
3.3.7 Triple-Quadruple LC/MS/MS
Agilent Technologies 6460 Triple-Quadrupole LC/MS/MS in multiply reaction
monitoring (MRM) mode was applied in the investigation of metabolites of CBZ,
especially for the 3 compounds (CM1, CM9, CM11 and CM12) which the
resolution were low in Q-TOF. Data was analyzed in Agilent MassHunter
Qualitative Analysis software. After the formula of metabolites was confirmed by
LC-Q-TOF-MS, different retention times of individual metabolites could be
recognized by Triple quad with less noise than in Q-TOF. (Fig. 3.9)
The specific parameters, including optimized fragmentor voltage and collision
energy (CE) for different MRM transition has been determined by flow injection
analysis without column (FIA) with MassHunter Optimizer software (Appendix II).
Four transitions were selected to monitor for one compound.
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C15H12N2O

C15H14N2O3

(CBZ)

(CM2)

C15H12N2O2 (CM1)

C14H11NO2 (CM3)

C14H9NO

(CM4)

C13H9N (CM5)

C13H9NO

(CM6)

C15H13NO2 (CM7)

Figure 3.9 The chromatograms of CBZ and its metabolites.
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C14H9NO2

C16H14N2O2

(CM8)

C15H11NO3 (CM9)

(CM10)

C14H8ClNO

(CM12)

C13H8ClNO

(CM14)

C15H12ClNO2 (CM11)

C13H8ClN (CM13)

C14H8ClNO2

(CM15)

Figure 3.9 (Cont.) The chromatograms of CBZ and its metabolites .
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The information of produced ions gave a better understanding of the structure
of metabolites than the targeted MS/MS, it provided all the fragment information
of parent compound to help to analyze, several same transitions could suggest
the structural similarity. For example, CM4, CM5, and CM7 shared most of their
product ions (Table 3.3).
Table 3.3 The optimizer data of CM4, CM5 and CM7.

Precursor ion

C14H9NO

(CM4)

Precursor ion
(m/z)

Shared product ions
(m/z)

208

C13H9NO

(CM5)

180

C15H13NO2

(CM7)

240

Independent product ions
(m/z)

75, 102, 154 ,
180, 152 , 128,
127 , 77, 101, 51

75, 102, 153 , 140
208,153, 154

The bold values were t he mass of precursor ions. The italic values were estimated as the same
fragments adducted with vary hydrogens.

The different elution times of the same formula was considered as isomers.
In addition, the existence of isomers could also be suggested with distinctive
product ions by the same fragmentor voltage at different retention time.
3.3.8 The proposed mechanism of degradation catalyzed by CPO
With all information above, the pathway for CBZ metabolism catalyzed by
CPO was proposed (Fig 3.10.) The main pathway of degradation was to form the
10,11-expoxy carbamazepine (CM1), the C10-C11 bond was likely the most
reactive site. The 10,11-dihydroxy carbamazepine (CM2) produced by addition of
H2O, with both trans and cis isomers. They were major transient intermediates
further underwent cleavage of the carbamoyl moiety and rearrangement of
heterocycles, from azepine ring to a pyridine structure, to form 9-acridine-
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caboxaldehyde hydrate form (CM3). Hydroxyl group of CM3 was exchanged with
methanol in phosphate buffer (pH 3.0), to generate methylated product CM7.
Dehydration was the reaction happened at the same time, 9-acridinecaboxaldehyde (CM4) was generated. CM8 was hydroxylated from CM4. Both
CM3 and CM4 were not observed on mass spectra, because they transferred to
their product quickly at the beginning of reaction (Fig. 3.8). Acridine (CM5) was
formed from CM4 by cleaving aldehyde group of CM4. Further, the derivatives of
CM5 was generated as CM6’ and CM6. CM6’ was the hydroxylated product of
CM5, hydroxylation was at 9 position due to its low electron density. The oxidized
metabolite, acridone (CM6) was from CM6’ by kept oxidizing at hydroxyl group
and considered as more abundant than CM6’ according to its stable structure.
The minor path way was from CM1’a, hydrolysis of the carbamoyl moiety, to
form a carboxylic acid group CM9a, and further CM9a’ underwent the oxidation to
form CM9b. CM1’a was transformed from CM2 by losing water molecule, by
exchanged the carbamoyl moiety, CM9a was also formed. Oxcarbazepine
(CM1’b) was oxidation of CM1’a on the hydroxyl group, and CM1’b produced
CM9b by the same way as CM1’a to CM9a. The methylation of hydroxyl group of
CM1a generated CM10. CM11, CM12, CM13, CM14 and CM15 were the
chlorinated

metabolites

from

CM7,
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CM4,

CM5,

CM6,

respectively.

Figure 3.10 The proposed mechanism of the degradation of CBZ catalyzed by CPO.
presented by primary structure of each metabolite.
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3.4 Discussion
The process of CBZ degradation catalyzed by CPO was efficient, 100 % CBZ
was depleted at the concentration from 2.5 mg to 14.8 mg/L for minutes, or ≥96%
with 16.5 mg/L for 4 minutes, all in nanomolar level CPO. The degradation rate
and concentrations were conservative, removal ability are mostly likely more than
parameters used in the experiment due to the LC samples were not monitored by
shorter time period.
Compared with some biological treatment in water, such as white rot fungus,
the efficiency of CPO-catalyzed reaction was dramatically improved. For
example, it was reported that 57% to about 70% of CBZ was removed by
Trametes versicolor, and 46% was degraded by Ganoderma. Lucidum for 7
days, at the original concentration of 10 mg/L (ppm). [58]
The UV treatment, the most efficient common water treatment in degrading
CBZ, compared with ClO2 oxidation and active sludge treatment. The UV
radiation with 0.1 mg/L CBZ, could remove 93% of parent compound after 10
minutes. The concentration of CBZ was 0.1 mg/L in ClO2 to remove 54% CBZ; in
active sludge treatment with 0.2 mg/L CBZ, 16% of drug was removed. [62] For
the other active sludge degradation experiment with 30 µg/L CBZ, the removal of
CBZ was not observed.[63] TiO2/UV method could reach 74% CBZ conversion
for 2 hours with TiO2 at 100 mg/L.[59] The complete CBZ degradation (10mg/L)
by Fenton-like oxidation was achieved at 2 mg/L iron for 1 hour, at 50 ℃.[64]
The new CBZ biodegradation was investigated by using freshwater microalgae
for 10 days the percentage of degradation was 30%-37%, with initial CBZ
58

concentration at 1mg/L (ppm). With the increased of CBZ concentration, the
degradation rate was decreased.[57] Ozonation of CBZ was likely the rapidest
degradation treatment to CBZ in drinking water treatment system by ppm level
ozone.[65] However, to consider about the application in large scale
environment, CPO showed the stronger degradation ability to high concentration
of CBZ at simple conditions (low concentration of catalyst, easy operation and
proper reaction time), which was a potential choice industrial wastewater
treatment.
Most of CBZ metabolites generated by CPO-H2 O2-Cl- system were the same
as products in the common water treatment and in environment.[58, 59, 62, 63,
66] The CPO-H2 O2-Cl- system could be used as the environmental model to
learn the chlorinated and oxidized reaction of specific pollutants.
To consider the toxicity and the persistence of CBZ products, the possible
environmental impact of metabolites should be emphasized. Although simple
acridines were not carcinogens, acridine and its derivatives were suggestive of
mutagenic activities.[67] Acridine and aridone showed more toxic than CMZ itself
in different ecotoxicity assays.[53]
There are still abundant acridine, acridone, and their derivatives after
degradation catalyzed by CPO. The acridine and acridone are more susceptible
to biological treatments. CPO might be applied in active sludge or with other
microorganism to digest the major metabolites. The UV treatment showed a
outstanding removal of acridine and acridone. CPO catalyzed degradation could
be coupled with UV-treatment to increase the degradation efficiency. The
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investigation of improving the depletion of toxicologically relevant metabolites of
CBZ, such as by coupling CPO catalyzed degradation with other treatment
should be considered in the future experiments
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CHATPER IV.
IV. CPO-CATALYZED DEGRADTION OF SULFAMETHAZINE
4.1 Background
Over 10,000 tons level of antibiotics are estimated to be used in the U.S.A per
year. [68] Sulfonamide pharmaceutical substances are widely used in human and
veterinary antibacterial treatments and they are

frequently detected in

wastewater and surface water with the active sulfonamide concentration detected
as 20 mg/L.[69] Sulfamethazine or sulfadimidine (SMZ) belongs to heterocyclic
sulfonamides, and the concentration of SMZ has been detected to 8.7 mg/kg in
manure.[70] Nine sulfonamide antibiotics were detected in surface water with
SMZ as the highest one with concentration of 78.3 ng/L, SMZ resistant bacteria
was found in the sample.[8] The detection of SMZ resistant bacteria implied the
extensive use of SMZ increased the risk of antibacterial resistance..
CPO showed its ability to degrade/ detoxicate drugs in our previous study,
and the aim of this experiment was to investigate the potential application of CPO
in degradation of antibiotics. To evaluate CPO-H2O2 -Cl- system, the reaction
efficiency of CPO in the degradation of SMZ would be investigated and the
structures of metabolites and degradation pathway would be proposed.
4.2 Experimental Procedure
4.2.1 Material
All material and chemicals used were the same as described in section 2.2.1.
4.2.2 UV-Visible spectrophotometry
A VARIAN UV-Vis spectrophotometer (Cary 200 Bio) was used to collect the
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UV spectra of the degradation products. SMZ was dissolved in methanol to make
3.59 mM stock solution. The drug solution was scanned by dissolving 0.06 mM
SMZ in 100 mM KH2PO4 buffer with 20 mM KCl at pH 2.75, mixed with0.06 mM
H2O2. UV spectra were recorded after the addition of 5 nM CPO for 1minute, 2.5
minutes and 4 minutes.
4.2.3 Liquid chromatography and mass spectrometry
4.2.3.1 Sample preparation
To investigate the degradation efficiency, SMZ was dissolved in methanol to
make a stock solution (3.59 mM), 62.45 µM (17.38 mg) of SMZ was mixed with
1.3 nM CPO for 30 minutes at room temperature. H2 O2 stock solution (41.16 mM)
was added to reaction system at 56.5 µL/minute to make the final concentration
of H2O2 achieved 314 µM. Mixture was centrifuged at 3,000 g in Centriprep®
centrifugal filter unit with a 30,000 Dalton cut-off membrane (EMD Millipore,
Billerica, MA, USA). The filtrate was collect after centrifuged for 1 min. Ethyl
acetate was used to extract the filtrate while shaking vigorously. The get rid of the
organic solvent, The supernatant was evaporated to dryness. The dried residues
were dissolved in H2O /methanol (95:5 v/v) to make the final concentration
approximate 1 mg/L (ppm). Sample was stored at -20 ℃ in a freezer or
immediately detected by LC-Q-TOF-MS mass spectrometer system.
To detect all metabolites of SMZ, the same experiment above was carried out
(3.59 mM SMZ, 314 µM H2 O2 and 1.3 nM) for 1.5 hour, extracted directly by ethyl
acetate. And nitrogen gas purge was used to get sample dried. The dried
metabolites were dissolved in 2.0 mL H2 O/methanol (95:5 v/v) to make the final
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concentration approximate 5 mg/L (ppm). Centrifuge the sample with 1200g for
10 minutes, 1.5 mL supernatant was removed by syringe. Filtration was applied
by using 0.22 µM polyethersulfone syringe filter. The sample was stored at -20 ℃
in a freezer and detected both in LC-Q-TOF-MS.
To investigate the mechanism of degradation in CPO-H2O2 -Cl- system, the
sample reacted with low concentration of H2O2 was prepared. 6.86 µM H2O2 was
added directly to Centriprep® centrifugal filter unit (30,000 Dalton cut-off) with
35.90 µM SMZ, catalyzed by 1.3 nM CPO in the 100 mM phosphate buffer with
20 mM KCl for 1 minute, 3 minutes and 5 minutes, filter units were centrifuged at
3000g for 1min at room temperature, and extracted the filtrate by ethyl acetate,
purged the organic phase with nitrogen gas to dryness. The dried metabolites
were dissolved in H2 O/methanol (95:5 v/v) to make the final concentration
approximate 1 mg/L (ppm), and detected by LC-Q-TOF-MS system immediately.
Experiments ran in triplicate.
To investigate the brominated products, the reaction was also carried out in
the buffer contained KBr instead of KCl, 62.45 µM SMZ, 2 mM H2O2 , catalyzed
by 2 nM CPO for 30 minutes. After extraction and purge procedure, the final
concentration dissolved in the H2 O/methanol (95:5 v/v) was approximate 1 mg/L
(ppm).
4.2.3.2 Instrumentation and chromatographic separation
Instrumentation and chromatographic separation were the same as in section
2.2.3.2. without the application of Triple-Quandrupole LC/MS/MS mass
spectrometry.
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4.2.3.3. Data Mining and Database development
The data Mining and Database development were the same as in section
2.2.3.3 without the application of FIA.
4.3 Result and discussion
4.3.1 UV-Vis study of CPO-catalyzed degradation of carbamazepine
UV-Vis Spectra of SMZ (0.06 mM) and H2O2 (0.06 mM) were scanned in 100
mM KH2PO4 buffer with 20 mM KCl at pH 2.75 (Fig.4.1). The Spectrum of SMZ
showed the absorption at 241 nm, 263 nm and 306 nm. 1 minute after addition of
5 nM CPO, the 241 nm absorption increased, and stopped increasing at 2.5
minutes, the 263 nm peak kept decreasing. And the wavelength at 306 nm
increased from 1minute to 2.5 minutes. The UV spectrum at 4 minutes was
monitored, the line was the same as the wavelength at 2.5 minutes. H2 O2 was
added to the mixture solution, to make the total concentration of H2O2 increase to
0.30 mM, after 1 minute, the 241 nm peak decreased and a strong absorption
was observed at 273 nm (Fig. 4.1). There was no wavelength could be used to
measure kinetic parameter of SMZ degradation catalyzed by CPO.
The same reaction was carried out under the same condition except for the
chlorine ion (KCl) in phosphate buffer. Without KCl, the absorbance did not
change after the addition of CPO. Chlorine ion is imperative in the degradation of
SMZ in CPO-H2O2-Cl- system.
4.3.2.1 CPO-H2O2-Cl- system
To investigate the degradation efficiency of SMZ in CPO-H2O2 -Cl- system,
62.45 µM SMZ was reacted with 314 µM of H2O2 and CPO (1.3 nM) for 30
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Figure 4.1 UV spectrum of SMZ degradation catalyzed by CPO

minutes, the sample was detected by LC-Q-TOF-MS, SMZ was not observed, the
4.3.2 LC-Q-TOF- MS
Degradation efficiency by nanomolar level of CPO could achieved 100%,
suggesting the potential of the application of CPO in large-scale waste water
treatment.
Samples were detected in Agilent Technologies 6530 Accurate-Mass LC-QTOF-MS in full scan MS mode, the accurate mass data of the molecular ions
were processed through the Agilent MassHunter Qualitative Analysis software.
To detected all metabolites, samples were concentrated 5 folds, there were 8
SMZ metabolites (coded from SM1 to SM8) confirmed by different retention times
and accurate mass-to-charge ratios (m/z). SM9 was detected only in the reaction
with limited H2 O2 within 5 minutes as an intermediate product. The elemental
formula, retention time, the relative mass difference between the observed mass
and the mass of the target compound (in parts per million), and the difference
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between the observed mass and the mass of target compound (in milliDaltons)
were collected (Table 4.1).
Table 4.1 Accurate-Mass QTOF-LC/MS data for the identification of SMZ and its metabolites
catalyzed in CPO-H2O2-Cl- system.
Code

Formula

Retention time
(min)

Experimental mass
(m/z)

Theoretical mass
(m/z)

Diff
(ppm)

Diff
(mDa)

278.0832

278.0837

-1.93

-0.54

SMZ

C12H14N4O2S

SM1

C12H14N4

4.245
3.219

214.1211

214.1218

-3.27

-0.70

C12H13ClN4

4.106

248.0829

248.0829

0.00

0.00

C12H12Cl2N4

7.295

282.0440

282.0439

0.23

0.07

SM4

C12H11Cl3N4

7.400

316.0044

316.0049

-1.71

-0.54

SM5

C12H13ClN4O2S

4.894

312.0447

312.0448

-0.13

-0.04

SM6

C12H12Cl2N4O2S

5.414

346.0054

346.0058

-1.04

-0.36

SM7

C12H13ClN4O3S

2.980

328.0398

328.0397

0.25

0.08

C12H11Cl3N4O2S

7.267

379.9668

379.9668

-0.16

-0.06

C12H14N4O3S

1.020

294.0790

294.0787

1.17

0.34

SM2
SM3

SM8
SM9

All the relative mass difference of the standard drug (SMZ) and metabolites
were less than 4.0 ppm. The mass differences of all compounds were less than
1.0 mDa. This method was proved to be efficient for determination of the
metabolites of SMZ.
The mass spectra of each individual metabolite were collected in positive
mode by MassHunter Workstation software (Appendix I). Since it was in positive
mode, all the compounds were detected as molecular ion [M + H]+. SM7 and
SM9 were detected as molecular ion [M + Na] + adduct (351.0287 m/z and
317.0677 m/z, respectively), the sodium adduct formation was favored in the ion
source probable due to the ion pairing effect on the functional group responsible
of ionization.
For chlorinated metabolites with one chlorine atom in compound (SM2, SM5
and SM7), the isotope peaks were detected as the conformation of addition of
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chlorine atom, the two major peaks of each spectrum separated by 2 m/z units
and peak heights are in the ratio of 3:1, proved these molecules contain one
chlorine atom. For SM3 and SM6, there were 3 lines in the molecular ion region
(M+, M+2 and M+4) with gaps of 2 m/z units between them, and with peak
heights in the ratio of 9:6:1, it was confirmed that both compounds contain 2
chlorines. For SM4 and SM8, compounds had the pattern 27:27:9:1.[71]
The structures of each metabolite were confirmed in targeted MS/MS by
retention time and fragment ions (Fig. 4.2). There were 2 types of metabolites
based on their structures. The first type products were SO2 extrusion structures.
(SM1, SM2, SM3 and SM4). SM1 was the product lost the sulfonyl group of SMZ,
SM2, SM3 and SM4 were the chlorinated metabolites of SM1. The other
structures were directly chlorination of SMZ (SM5, SM6 and SM8), and the
hydroxylation product of SM5 was SM7. SM9 was the metabolic intermediate of
SM7, the hydroxylated product of SMZ, it could only be detected at the beginning
of the reaction.
The concentrations of all metabolites were measured as compound area by
MassHunter Workstation software, and presented by percentage of all
compounds as pie chart, percentage less than 1% were showed in the second
pie chart at right side (Fig. 4.3)
To investigate the mechanism of degradation process, a experiment was
carried out for limited reaction time (1,3 and 5 minutes) with low concentration of
H2O2 (6.86 µM), the ratio of the concentration of drug and H2O2 was about 5:1.
Only part of SMZ was degraded, and 3 metabolites were detected which could
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C12H14N4O2S (SMZ)

C12H14N4 (SM1)

C12H13ClN4 (SM2)

C12H12Cl2N4 (SM3)

C12H11Cl3N4 (SM4)

C12H13ClN4O2S (SM5)

C12H12Cl2N4O2S (SM6)

C12H13ClN4O3S (SM7)

Figure 4.2 The targeted MS/MS spectra of APAP and its metabolites.
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C12H11Cl3N4O2S (SM8)

C12H14N4O3S (SM9)

Figure 4.2 (cont.) The targeted MS/MS spectra of APAP and its metabolites.

Figure 4.3 The percentage of each metabolites measured by compound area. Metabolites
shared the same structure presented by the same color (pink color represent the
desulnonated structure, purple represent the SMZ-based group and blue presents the
hydroxylated group).

be

suggested as the first formed metabolites (Fig 4.4). SM1 was the most
abundant metabolite within 5 minutes, and SM5, SM9 generated at the same
time in lower amounts, suggested that the first step of degradation was the
oxidation, chlorination and the loss of sulfonyl group, SM1 formed preferentially.
The area of SM1 kept stable at first 3 minutes and showed decreased
tendency at 5 minutes, it might due to the transformation of SM1 to chlorinated
metabolites which under the limit of detection. The percentage of SM1 was
26.35% in the reaction with higher concentration of H2O2 for longer reaction time,
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whereas SM6 was the primary product finally, suggested that the desulfonylation
reaction was predominant at the first reaction stage, and then the rate of
chlorination significantly increased.
SM5 had the increased tendency form 1 minute to 5 minute, the finally
concentration of SM5 was low but its chlorinated product SM6 was the major
metabolites, SM5 was suggested as the major intermediate metabolite. SM9 was
not observed after reaction with high concentration H2 O2 for 30 minutes, but its
chlorinated product was detected as 0.43% of all metabolites, it was suggested
that hydroxylated metabolites were the byproducts in the reaction. Chlorination
and desulfonylation were the major reactions, hydroxylation was the minor
reaction. (Fig.4.3).
For desulfonylated metabolite SM1 and its chlorinated products SM2, SM3
and SM4, the total concentration of them was 39.83% and the 3 chlorine atom
addition structure (SM4) was only 0.91%. Chlorination of the desufonylated
structure by 3 chlorine atoms was not favored in the reaction which may due to
the structure of CPO binding pocket and the polarity in the pocket. The same
limitation of chlorine atoms addition also applied in SMZ based structure, the total
concentration of them was 60.17%, SM8 (0.86%) were the minor product of the
degradation catalyzed by CPO. Two chlorine atoms were preferentially inserted
to SMZ molecule (SM6, 58.20%) in contrast to the three chlorine atoms addition.
(Fig 4.4)
The chromatograms of SMZ and its metabolites were collected with their
proposed structures (Fig. 4.5). In the chromatograms of SM2, SM3, SM4, SM5,
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Figure 4.4 The area of metabolites wit h limited H2O2 at 1 minute, 3 minutes
and 5 minutes detected by Accurate -Mass LC-Q-TOF-MS. All experiments
were duplicates and dat a reported were mean values of two independent
measurements.

SM7, SM8 and SM9, there were isomers identified by different retention times.
The extrusion of SO2 structure (SM1) was reported previously with structural
rearrangement. There were two structures proposed for SM1 (Table 4.2). One is
N1-(4,6-dimethylpyrimidin-2-yl)benzene-1 (a), 4-diamine, another is 4-(2-imino4,6-dimethylpyrimidin-1(2H)-yl)aniline (b). Proposed structures were presented
by form (a) in all the spectra and chromatograms, form (a) was probably the
actual structure of metabolite in the reaction catalyzed by CPO because of its
less rearrangement than form
(b).

SM2-SM4

were

Table 4.2 Possible identities of C12H14N4 (SM1).

Structure

Reference

the

chlorinated products of SM1.In

[72-75]

SM2, there were 5 isomers
according to

the

5 different

retention times. The two major

[75-80]

isomers were chlorinated on
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position 1 and 2 because of the high electron density of aniline group and the
metabolite chlorinated at position 1 (Fig. 4.5) was assumed as the most
abundant product because of its electron density, –NH2 group on benzene ring
was an electron donating group (EDG) , whereas sulfonyl group was electron
withdrawing group. Other isomers were also suggested first be chlorinated or
hydroxylated on the aniline group at the carbon atoms which located close to
amine.
SM5 had 5 different chlorinated sites which corresponded to 5 different
retention time, major metabolites were chlorinated at position 1,2 and 3, the 3rd
position was on the dimethylpyrimidine group (Fig 4.5). The other two were
proposed to assign to the two amine groups. SM6 only showed one retention
time, there was one structure was stable, other structures may exist but with the
amount under the limit of detection. The chlorine atoms probably added to the
aniline group near primary amine due to the high electron density and it was a
typical chlorination catalyzed by CPO.[39] SM8 was the byproduct with one
more chlorine atom addition based on SM7, the two retention times suggested 2
isomer structures, one additional chloride sites were on the aniline group near NH2 or on the dimethylpyrimidine.
SM7 and SM9 were the hydroxylated products of SMZ, although in TiO2/UV
method, the pyrimidinyl moiety of SMZ was suggested to be hydroxylated, in
CPO reaction, phenyl portion were proposed to be hydroxylated according to the
MSMS spectrum. [81] The hydroxylation of aromatic amine in SMZ was also
reported in the biodegradation catalyzed by white rot fungus.[72] However,
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C12H14N4O2S (SMZ)

C12H14N4 (SM1)

C12H13ClN4 (SM2)

C12H12Cl2N4 (SM3)

C12H11Cl3N4 (SM4)

C12H13ClN4O2S (SM5)

C12H12Cl2N4O2S (SM6)

C12H13ClN4O3S (SM7)

.
Figure 4.5. The chromatograms of CBZ and its metabolites .
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C12H11Cl3N4O2S (SM8)

C12H14N4O3S (SM9)

Figure 4.5. (cont.) The chromatograms of CBZ and its metabolites .

according to CPO chlorination preference, the hydroxylation was recommended
mainly at phenyl portion.
The mechanism of degradation catalyzed by CPO was proposed considering
all information above, the pathway for SMZ metabolism catalyzed by CPO was
proposed, each metabolite showed by one of its proposed chemical structures
instead of all isomers. For CPO-H2O2 -Cl- system (Fig 4.6), the chlorinated steps
with one and two chlorine atoms addition and desulfonylation of SMZ were the
major pathways. The minor path way was hydroxylation and chlorination with
three chlorine atoms.
4.3.2.2 CPO-H2O2-Br- system
To investigate the halogenation of SMZ catalyzed by CPO, 20 mM KBr was
applied in the buffer instead of KCl, the CPO-H2O2-Br- system reaction was
carried out at the room temperature, and the product spectrum was obtained
(Appendix I) There were only 3 metabolites detected. All of them were
brominated products. (Table 4.3) [71] There were two peaks (357.0027 m/z and
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Figure 4.6. The proposed mechanism of the degradation of SMZ catalyzed by CPO-H2O2-Clsystem presented by primary structure of each metabolite.
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Table 4.3 Accurate-Mass LC-Q-TOF-MS data for the identification of SMZ and its metabolites
catalyzed in CPO-H2O2-Br system.
Retention time
(min)

Experimental mass
(m/z)

Theoretical mass
(m/z)

Diff
(ppm)

Diff
(mDa)

SM5-Br C12H13BrN4O2S
SM6-Br C12H12Br2N4O2S

5.390

355.9948

355.9943

1.65

0.59

6.095

433.9042

433.9048

-1.28

-0.55

SM8-Br C12H11Br3N4O2S

8.258

511.8144

511.8153

-1.66

-0.85

Code

Formula

368.9995 m/z) in approximately 1:1 ratio in the mass spectrum of SM5-Br,
confirming compound contained 1 bromine atom. For SM6-Br, there were three
peaks (434.9117 m/z, 436.9090 m/z and 438.9074) in 1:2:1 ratio, suggested 2
bromines addition to the parent compound. The ratios of 3 bromine atoms
contained molecule are 1:3:3:1, which was observed in the mass spectrum of
SM8-Br, suggested the number of bromine in this metabolite.
In the CPO-H2O2 -Br- system, neither the loss of sulfonyl group, nor the
hydroxylation was observed (Fig 4.7). Compared

SM5-Br
0.07%

with the chlorination of SMZ, bromination was
favorable to form the product with 3 halogen atoms

SM8-Br
48.83%

SM6-Br
51.10%

addition (48.83%).
Halogenation, hydroxylation and desulfonylation
were suggested as competitive reactions in the

Figure 4.7 The perc entage of
the
three
metabolites
measured by compound area
(catalyzed by CPO-H2O2-B rsystem).

SMZ degradation catalyzed by CPO. When buffer
contained bromide, with competitive pathway was
predominantly changed

to

halogenation. This

result was consistent with our previous result that the rate of halogenation in the
presence of bromide was higher than chloride.[28]
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C12H13BrN4O2S (SM5-Br) MSMS spectra

C12H13BrN4O2S (SM5-Br) chromatogram

C12H12Br2N4O2S (SM6-Br) MSMS spectra

C12H12Br2N4O2S (SM6-Br) chromatogram

C12H11Br3N4O2S (SM8-Br) MSMS spectra

C12H11Br3N4O2S (SM8-Br) chromatogram

Figure 4.8 The mass spectra and chromatograms of SMZ brominated metabolites.

The structures were confirmed by targeted MSMS, and the chromatograms of
each metabolite were collected. (Fig 4.8).
There was only one peak in each chromatogram, demonstrated that there
was no isomer of brominated product. Bromination showed higher halogenated
selectivity in the SMZ, it was presumably due to the formation of Br2 during the
CPO catalyzation. The halogenation might occur in the solution or the wide
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channel of CPO, reacted with the free bromine. This assumption also consistent
with the only one retention time of SM6, Cl2
might release and reacted with SMZ
directly by two chlorinated sites. It was
suggested

that

HClO

formed

catalyzation

to

however

chlorination

in

chlorinate

in

the

substrate,

of

SMZ

by

hypochlorite, the product was only reported
as SM5, HClO would not be the only
crucial

intermediate

involved

in

the

chlorination.[82]
For CPO-H2O2-Br- system, there was
only one pathway to elucidate the
mechanism of SMZ halogenation. (Figure
4.9)
4.4 Discussion
The

process

of

SMZ

degradation

catalyzed by CPO was efficient, 100 %
SMZ was depleted at the concentration Figure 4.9.The mechanism of SMZ
from 17.38 mg/L for minutes by the

bromination catalyzed by CPO

nanomolar level CPO. The degradation rate and substrate concentrations were
conservative, removal ability are mostly likely more than parameters used in the
experiment due to the LC samples were not monitored by shorter time period.
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The major metabolite in environment was N4-acetyl-sulfamethazine.The
desulfonylated products generated by CPO-H2O2-Cl- system are more
susceptible to future biological degradation.[70]
Compared with some biodegradation treatment in water, such as white rot
fungus, the efficiency of CPO-catalyzed reaction was dramatically improved. For
example, it was reported 9 mg/L SMZ was removed by Trametes versicolor for
20 hours.[72] The 62%±4% SMZ was removed within 8 minutes when 36 µM
SMZ reacted with 360 µM MnO2.[8]
It was reported that in different types of treatments (photolysis, UV/H2O2,
UV/persulfate and persulfate oxidation) with 20 µM SMZ for 45 minutes, the
removal rate of SMZ achieved 15.1% to 96.5%. The UV/H2O2 achieved 87.5%,
the most effective method was UV/persulfate, however this reaction required 200
µM sulfate to accomplish 96.5% degradation, 500 µM sulfate to accomplish
100% degradation. As it stated by the author, the persulfate addition may cause
environmental problem.[79]
The degradation of SMZ was not significantly observed after 8 hours when
treated by sodium hypochlorite, and used more than one month to degrade
substrate.[83]
CPO catalyzed degradation has the potential to apply in large scale wastewater
treatment considering about the nanomolar level enzyme and the rapid sample
preparation.
The oxidation and chlorination products of SMZ generated in CPO-H2O2 -Clsystem could be found in most of the water chlorination treatment and
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biodegradation process.[72, 75, 83] CPO-H2O2 -Cl- system might be used as the
environmental model to learn the chlorinated and oxidized reaction of specific
pollutants.

80

CHAPTER V.
V. ENGINEERING THE HYDROGEN BOND OF CPO BY MUTANT H105R
5.1 Introduction
Glutamic acid 183 (Glu 183) of CPO located closely to the heme iron in the
distal pocket, suggested its function to in the cleavage of the peroxide O-O bond.
[20] It is an important acid-base catalyst in the formation of compound I. In a
mutagenensis study, Glu 183 was replaced by histidine residue, the mutant’s
chlorination and dismutation activity were decreased to 15% and 50%,
respectively.[23] The result implied that the Glu 183 affects predominately

Figure 5.1 The Proposed mechanism of His 105 in the cleavage of the peroxide O-O bond.
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chlorination activity, but not essential for it. The hydrogen bond linked to 183 and
the distal pocket structure might affect the enzyme activity, mutant E183H could
still form hydrogen bond with histidine 105(His 105) to facilitate the cleavage of
peroxide O-O bond.
His 105 was located in the heme distal pocket, formed hydrogen bond with
glutamic acid 183. His 105 is 3.5 Å form the propionate carboxyl group, it might
be critical in peroxide O-O cleavage by forming a hydrogen bond with Glu183
which position the carboxyl group toward the heme iron. The hydrogen bond
between H105 and E183 was suggested to play an essential role in modulating
the chlorination activity. (Fig. 5.1) [1, 21] When H105 was replaced by a small
and nonpolar amino acid alanine (H105A) to decrease the polarity and destroyed
chlorination decreased. [85]
To investigate the function of the hydrogen bond between histidine and
glutamic acid, mutant H105R was created by changing histidine 105 to arginine
to increase the hydrogen bonding strength.
5.2 Experimental Procedure
5.2.1 Materials
A filamentous fungus Aspergillus niger (A. niger, MGG029) were purchased from
American Type Culture Collection (Manassas, VA). Gene expression vector
pCPO3.I-Amds which is coding for WT CPO and co-transformation plasmid
pAB4.1 with PyrG selection marker (GenBank accession no. AJ300448) were
obtained TNO Microbiology and Systems Biology, Netherlands. Ultra-Pfu DNA
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polymerase and The QuikChange II XL sitedirected mutagenesis kit were
purchased from Stratagene (La Jolla, CA). Lysing enzyme (L1412) was from
Sigma- Aldrich (St. Louis, MO) Purified oligonucleotide primers were obtained
from Eurofins MWG Operon (Huntsville, AL). All other chemicals were purchased
from Thermo Fisher scientific (Waltham, MA). De-ionized water was produced
by using a Milli-Q® Biocel™ Ultra-Pure water purifier system equipped with 0.22
µM membrane filter cartridge (EMD Millipore, Billerica, MA, USA), purification
cartridge and an organic removal cartridge (Evoqua Water Technologies, Lowell,
MA, USA).
5.2.2 Construction of H105R mutant and plasmid propagation
To investigate the function of His 105 and the relation between His 105 and
Glu183, the H105R mutation was created by site -directed mutagenesis. Vector
pCPO3.I-Amds, a 14 kb plasmid was used as template. A.nidulans acetamidase
gene (AmdS) was inserted into NotI restriction enzeme digestion site as a
selection marker, to allow the mutant contains Amds to grow on acetamide plate,
consuming acetamide as the sole source of nitrogen. The full encoded CPO
gene, pCPO3.I is placed under control of the A. niger glucoamylase promoter
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(PglaA) and A. nidulans anthranilate synthetase terminator (TtrpC). (Fig. 5.2)

Figure 5.2 The CPO expression vector pCPO3.1-AmdS for transformation of A.niger strain.[2]

Encoded primers for H105R mutant was 5’-gag ccc cac gct ttc gag cgc gac
c-3’(primer 1) and 5’-gcg gga gaa gga gtg gtc gcg ctc g-3’(primer 2), both with the
melting temperature of 74.42℃.The PCR was carried out by QuikChange II XL
sitedirected mutagenesis kit and Eppendorf thermal cycler (Mastercycler
gradient) , PfuUltra HF DNA polymerase was added to reaction.The PCR
reaction was set up at 98 ℃ for 50 seconds, followed by 18 cycles of 98℃ for 30
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seconds for denaturation, 63 ℃ for 30 seconds for annealing, 72 ℃ for 14
minutes for extension, the last cycle was hold at 72 ℃ for 10 minutes.
DPN I restriction endonuclease was applied to digest the templates. PCR
product was propagated in E. coli strain (H105R). Plasmids from E. coli was
extracted by QIAGEN DNA extraction mini kit (QIAGEN, CA). The extracted DNA
was examined by DNA electrophoresis and confirmed by DNA sequencing (Fig.
5.3)
5.2.3 Transformation into A. niger and selection for expression
The A. niger MGG029 strain was inoculated in 50 mL minimal medium (MM)
containing maltose (5%), glucose (1%), casamino acids (0.5%), yeast extract
(0.5%), NaNO3 (70mM), KCl (7 mM), K 2HPO4 (6 mM), MgSO4 (2 mM), uridine (10
mM), carbenicillin (50 mg/L), the Hutner trace elements solution (50 µL).[84] The
culture was incubated for 37 ℃ at 250 rpm for 1 day and change to 30 ℃ for 2-5
days, homogenizer was used to disrupted mycelia for 20 seconds, repeated 3
times. Then the culture was transferred to 1 L media with the same compositions
as in 50 mL MM, incubated at 30 ℃ for 20 hours at 250 rpm.
Mycelia was resuspended in 1.7 Osm solution (0.27 M CaCl2 and 0.6 M NaCl)
after filtered through sterile myracloth. Protoplasts were incubated with lysing
enzyme (L1412) at 37 ℃ for 4 hours at 150 rpm, resuspended protolasts and
incubated on ice for 20 minutes, then centrifuged at 3500 rpm for 15-30 minutes
at 0 ℃ to get precipitate. The supernatant was decanted, precipitate was
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washed twice by STC 1700 buffer (1.2 M sorbitol, 10 mM Tris-HCl, 50 mM CaCl2
and 35 mM NaCl at pH 7.5), resuspended by STC 1700 and incubated with10 µg
mutant plasmid and 1 µg pAB4.1 co -transformation plasmid at 25 ℃ for 25
minutes. The incubated protoplast was mixed with 60% PEG 4000 in 10 mM TrisHCl buffer at pH 7.5 and 50 mM CaCl2 carefully in three steps. The PEG-treated
protoplast was diluted to 10 mL with STC 1700 and collected through
centrifugation. The protoplast was resuspended in the leftover of STC1700 and
spread onto 1.2 M sorbitol selective agar medium plate, incubate for 3 -5 days at
22 ℃.
5.2.4 Expression of the H105R mutant protein
Mutant colonies on the selective plates were inoculated in MM (without
uridine and yeast extract, addition of 0.1 mM 5-Aminolevulinic acid hydrochloride
(heme precursor) for 22 ℃ at 250 rpm for 7 days.
MCD assay and ABTS assay of the culturing medium were used to
determine the protein yield by its chlorination and peroxidation activity,
respectively.
MCD assay was measured at 278 nm by UV-Vis spectroscopy. 0.17 mM
monochlorodimedone (MCD) was mixed with 50-500 uL culture medium in 100
mM KH2PO4 buffer with 20 mM KCl at pH 2.75, after addition of 2 mM H2O2,
absorbance at 278 nm was monitored for 1 minute.
1.7 mM 2, 2’-azino-bis-3-ethy-benzthiazoline-6-sulfonic acid (ABTS) was
mixed with 50 µL clear culture medium in 100 mM KH2PO4 buffer with 25 mM
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citric acid at pH 3.0, after addition of 2 mM H2O2 , the UV started to collect the
absorbance at 405 nm for 1 minutes.
Due to decreased tendency of ABTS activity after 2-3 days since inoculation,
and totally destroyed activity after Amicon stirring pressure cell, 0.05 mM
ferriprotoporphyrin IX chloride (hemin) was added to culture to stabilized the
mutant.
5.2.5 Purification of the mutant protein
After 7 days, the 12 Liter medium was filtered through myracloth and glass
fiber filter circles G6 to remove fungus, concentrated to 50 mL in the Amicon
ultrafiltration cell. 50 mL crude sample was dialyzed in 4 liters 25 mM phosphate
buffer at pH 5.9 for 12 hours, and repeat dialysis again with fresh buffer. The
sample was filtered by 0.45 µM membrane.
Ion exchange chromatography was applied by diethylaminoethyl (DEAE)
sepharose fast flow column with 50 mL DEAE resin. 25 mM phosphate buffer at
pH 5.9 with ionic strength gradient was used to wash the colunm, gradually
increase the concentration of NaCl from 0.0 to 0.5 M. Different eluted portions
were collected and concentrated by Centriprep ® centrifugal filter unit (30,000
Dalton). Absorption spectrum was scanned and SDS-PAGE was used to check
the existence of mutant.
All buffers used in column were filtered through 0.45 µM membrane and
degassed for 15 minutes to remove solid and gas particles. Purification by
columns was carried out in 4 ℃ to keep protein stable.
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was
used to check the molecular size of eluted products.
5.3 Result and discussion
5.3.1 Mutant DNA sequencing

Figure 5.3 DNA sequence of H105R mutant.

In the sequencing result, the Histidine codon CAC was replaced by Arginine
codon CGC successfully. The GC content was as high as 72%, but PCR protocol
still work effectively.
5.3.2 Transformaiton and expression result
H105R mutant grown on 1.2 M sorbitol selective agar plate after
transformation suggested the transformation was successful. The colonies were
inoculated to 12 L medium and monitored
the expression of protein by MCD and
ABTS assays. There was no MCD activity
showed in mutant medium, only ABTS
assay could be used to evaluate the
expression. The ABTS activity was high
at the second day of inoculation, and
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Figure 5.4 H105R mutant grown on 1.2
sorbitol selective agar plate after 24 hours.

quickly decreased. (Fig. 5.5).
50 µM hemin was added to culture to stabilized the protein, repeated the
same protocol to 12 liters culture.
0.4

ABTS activity (µM/min)

0.35
0.3
0.25

0.2
0.15
0.1

0.05
0
9

30.5

34.5

Hours
Figure 5.5 The ABTS activity of H105R cultures since the second day of inoculation.
Samples were run in triplicate.

5.3.3 Purification
The purification of concentrated sample was collected to run SDS-PAGE with
samples from the crude medium and other portion of elution product. (Fig. 5.6)
The band of mutant was presented in SDS-PAGE, the concentrated sample
(lane2) was of transparent color, implying the heme was not incorporated into
protein.
In UV-Vis spectrum of concentrated sample (lane 2), the low-spin ferric heme
protein typically with a Soret band around 420 nm was not observed (Fig. 5.7),
indicating the heme incorporation was not e fficient in H105R mutant, the
recombinant H105R mutant was apoprotein.
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Figure 5.6 SDS-PAGE of mut ated protein. Lane 1-the crude sample before ion exchange;
lane 2-ion exchange eluted products (band of H105R in red rectangle); lane 3-products
eluted by buffer with 1M NaCl.

5.4 Discussion
The apoprotein H105R was suggested that arginine might change the distal
pocket due to its charge or structure, and even result in the instability of heme

Figure 5.7 UV-Vis spectra of H105R mutant.

90

porphyrin. Although H105 could be changed to alanine (A), the structure of CPO
would not change much due to the smaller size of alanine.
The chlorination activity was not found during all the process, suggested that
the chlorination acti ve site in CPO was not formed. The change of distal pocket
affected the chlorination dramatically and the role of H105 site was crucial in
supporting the CPO construction near the heme center.
The peroxidation decreased during culturing and amicon concentration,
implied that mutated protein was easy to be denatured. The H105 has the ability
to stabilize E183 by hydrogen bond, changing it to a larger and more polar amino
acid might destroy the structure and function of CPO by affected E183.
There is also possibility that the change from histidine to arginine might
directly change the tertiary structure of mutant protein. In conclusion, the amino
acid at 105 site could be changed to arginine but could not express active protein
due to heme incorporation failure.
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CHAPTER VI
VI. DEGRADATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DICLOFENAC AND
NAPROXEN BY CHLOROPEROXIDASE

THIS PAPER IS SUBMITTED AND ITS FORMAT IS KEPT

92

Degradation of Non-steroidal Anti-inflammatory Drugs Diclofenac and
Naproxen by Chloroperoxidase
Xiaohong Li a,†, Qinghao Heb,†, Haiyun Li a, Mancheng Hua,c , Shuni Li a,c ,Quanguo
Zhai a,c , Yucheng Jianga.c *, Xiaotang Wangb*
a School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi’an,
710062, P.R. China
b Department of Chemistry and Biochemistry, Florida International University,
Miami, Florida 33199,USA
c Key Laboratory of Macromolecular Science of Shaanxi Province, Shaanxi
Normal University, Xi’an, 710062,
P.R. China
†These authors contributed equally to this work
*Corresponding authors
Dr. Yucheng Jiang
Mailing Address: School of Chemistry& Chemical Engineering
Xi’an, No. 620 West Chang'an Road, Chang’an District
710119, P.R. China
E-mail: jyc@snnu.edu.cn
Phone: +86 29 81530763
Dr. Xiaotang Wang
Mailing Address: Department of Chemistry and Biochemistry
Florida International University
11200 S.W. 8th Street,
Miami, Florida 33199. USA
E-mail: wangx@fiu.edu
Phone: (305) 348-7544

93

Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac and naproxen,
are widely used for the treatment of arthritis, ankylosing spondylitis, and acute muscle
pain. However, most NSAIDs are usually not metabolized and simply pass through
human body. These drugs are difficult to be decomposed by general waste treatment
strategies and have caused serious environmental concerns. Here we report a rapid and
efficient enzymatic degradation of diclofenac and naproxen by chloroperoxidase (CPO),
a heme protein isolated from Caldarimyces fumago (C. fumago). Complete dagradation
of diclofenac and naproxen was achieved in only 9 and 7 min for diclofenac and
naproxen, respectively, under mild conditions with nanomolar enzyme concentration.
The degraded products were identified by both HPLC-MS and NMR, suggesting the
involvement of multiple steps in CPO catalyzed degradation of the two drug molecules.
Moreover, our work demonstrated that CPO treatment followed by existing
bioremediation technologies (activated sludge) greatly improved the efficiency and
completeness of decontaminating these two drugs from waste water. Most significantly,
our eco-toxicity test using green algae, Chlorella Pyrenoidos, showed that the products
had noticeably lower toxicity than the parent drugs, demonstrating the potential of CPO
in large-scale treatment of sewage contaminated with diclofenac and naproxen.
Keywords: enzymatic degradation; diclofenac; naproxen; chloroperoxidase; eco-toxicity
1. Introduction
Both diclofenac (2-[(2,6-dichlorophenyl)amino]benzeneacetic acid; sodium salt) and
naproxen (2-(6-methoxynaphthalen-2-yl)propionic acid) (Fig. 1) are non-steroidal antiinflammatory drugs (NSAIDs). They are widely used in the treatment of arthritis,
ankylosing spondylitis, acute muscle pain, and other symptoms associated with
inflammation (Grenni et al., 2013; Sathishkumar et al., 2012). The widespread
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application of these drugs coupled with their resistance toward metabolic breakdown in
human body inevitably resulted in the release of large amount of these drugs into the
aquatic environment. In recent years, diclofenac and naproxen has been detected in
surface water, groundwater, wastewater, and even in drinking water at concentrations
ranging from ng·L-1 to μg·L-1 (Zhang et al., 2008; Zhao et al., 2009). It has been reported
that naproxen has adverse effects on biota, such as impairing the lipid peroxidation
system of bivalves and altering microbial community structure to yield antibiotic
resistance in environmental microbial communities (Gagné et al., 2006). Diclofenac was
recently designated as a devastating environmental pollutant because of its
bioaccumulation in the food chain (Ilic et al., 2011). Therefore, effective degradation of
these drugs is of paramount significance for reducing their accumulation in the
environment.
Unfortunately, conventional sewage treatment is inefficient in removing or degrading
diclofenac and naproxen (Hartmann et al., 2008; Nakada et al., 2006). For example, no
noticeable breakdown of diclofenac was observed over a period of 28 days either when
it was the sole source of carbon or when an external carbon source was added for cometabolic degradation (Quintana et al., 2005). Batch tests using an activated sludge
system and membrane bioreactors also revealed very poor degradability of diclofenac in
comparison with other pharmaceuticals (Samaras et al., 2013). Other conventional water
treatment processes such as coagulation, sedimentation and filtration have all been
proven to be ineffective to remove these two drugs (Brillas et al., 2010; Westerhoff et al.,
2005). Consequently, physicochemical approaches including ultrasonic (Naddeo et al.,
2010), electrochemical oxidation (Faber et al., 2012), photocatalytic (Arriaga et al.,
2008), potassium permanganate oxidation (Álvarez et al., 2013) and ozone oxidation
(Naddeo et al., 2009) have been adopted to improve the removal of these drugs from
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drinking water or wastewater. However, limitations of these methods, such as cost,
efficiency, and secondary pollution from use of chemicals, warrant further investigations
on the removal/breakdown of these widely used drugs from environment.
Little evidence of diclofenac transformation by microbial communities is documented
in the literature. White-rot fungi (WRF) were found to be efficient in degrading both
diclofenac (Urrea et al., 2010) and naproxen (Urrea et al., 2010), but long treatment time
(1 h and 5 h, respectively) was needed. Enzymatic degradation is an ideal approach
because of the mild and environmentally friendly conditions employed. Thus, crude lignin
peroxidase (LiP, a heme-imidazole peroxidase) from Phanerochaete chrysosporium (P.
chrysosporium) has been used to convert diclofenac in various conditions and was found
to be highly effective (Zhang et al., 2010). In addition, fungal unspecific peroxygenases
(UPOs) have been shown to be able to hydroxylate/O-demethylate a diverse array of
pharmaceuticals (including diclofenac and naproxen)(Hofrichter et al., 2014; Kinne et al.,
2009; Piontek et al., 2013; Poraj-Kobielska et al., 2011; Wang et al., 2013). Inspired by
the results of LiP and UPOs, we studied the degradation of diclofenac and naproxen by
chloroperoxidase (CPO), a heme containing glycoprotein that is phylogenetically (hemethiolate proteins) and functionally (haloperoxidases) related to UPOs with higher
oxidation potential and thermal/chemical stability than LiP (Makino et al., 1976; Millis et
al., 1989). High performance liquid chromatography-mass spectrometry (HPLC-MS) and
nuclear magnetic resonance (NMR) spectroscopy were employed to identify the major
degradation products. Based on the products identified, reaction pathways are
postulated. Our results demonstrated that CPO can effectively convert both diclofenac
and naproxen into compounds that are significantly less toxic based on their inhibitory
effects and EC50 value on the growth of a freshwater green alga, Chlorella pyrenoidos.

96

2. Experimental
2.1 Enzyme preparation
Chloroperoxidase was isolated from the growth medium of C. fumago according to the
method of Morris and Hager (Morris et al., 1966) with minor modifications, using acetone
rather than ethanol in the solvent fractionation step. CPO with Rz =1.03 (A398/A280, 1.44
for pure enzyme) was prepared and stored in 100 mM phosphate buffer (pH 5.0) at 4 °C.
The halogenation activity of CPO used in this study was 4232 U·mL -1 based on the
standard monochlorodimedon (MCD) assay (Hager et al., 1966). The aromatic
hydroxylation activity (3563 U·mL-1) of the enzyme was determined by monitoring the
hydroxylation of naphthalene into 1-naphthol (Kluge et al., 2007). The classic peroxidase
activity of the enzyme determined using ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6sulphonic acid)) as substrate was 3071 U·mL-1 (Manoj et al., 2008).
2.2 Reagents and buffers
All reagents used in this study, including diclofenac, naproxen, dipotassium hydrogen
phosphate, potassium dihydrogen phosphate, hydrogen peroxide (30 % in aqueous
solution), ethyl acetate, and inorganic reagents for cultivating the green alga were
obtained from Xi′an Chemical Co. Ltd (Xi’an, China) with highest purity (≥ 98%). Other
chemicals such as methanol and acetonitrile (chromatography grade) as well as
standard degradation product of the two drugs, o-desmethylnaproxen and 4’hydroxydiclofenac (chromatography grade) were purchased from Sigma Aldrich (St.
Louis, MO USA).
Phosphate buffer (0.1 mol·L-1) was prepared by mixing appropriate volumes of 1
mol·L-1KH2PO4 and K2HPO4 stock solutions and diluting the combined solutions to 1 L.
Then the solution was adjusted to various pH with 1 mol·L-1 H3PO4. All solutions were
prepared using deionized water with a conductivity of 5.6×10-8 s·cm -1.
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2.3 Degradation of diclofenac and naproxen
Enzymatic degradation of both drugs was carried out in 0.1 mol·L-1 phosphate buffer in
a centrifugal tube with a total volume of 3.0 mL containing CPO (0.25-23 nmol·L-1), 20
mmol·L-1 KCl, and drugs (15 µmol·L-1) at pH 2~6 at 298K. The reaction was started by
adding H2O2 (0.015-0.3 mmol·L-1) in the absence of light under magnetic stirring and was
continued for 20 min. The supernatant of the reaction mixture was extracted 3 times
using ethyl acetate. The combined organic extract was concentrated by rotary
evaporation (0.09 MPa, 308K) to remove the solvent. The extracts were then dissolved
in acetonitrile and methanol, respectively, for HPLC (LC-20AT, Shimadzu) analysis. The
mobile phase consisted of 80:20 (v/v) acetonitrile and water for diclofenac and 90:10
(v/v) methanol and water for naproxen, and the flow rate was 0.5 ml·min-1. The detector
was set at 274 nm and 235 nm for diclofenac and naproxen, respectively. The
quantitative analysis of the target compounds was based on the standard curve
(correlation coefficients were > 0.999).
Degradation efficiency   C0  Ct  / C0   100%

(1)

The effect of reaction parameters (pH, concentration of enzyme/H2O2, and reaction
time) on degradation efficiency was investigated and optimized.
All experiments were triplicated and data reported were mean values of three
independent measurements.
2.4 Determination of products
Samples were treated as above for HPLC-MS analysis. An Esquire LC-ion trap mass
spectrometer (Bruker Daltonics, Germany) equipped with an orthogonal geometry
Electrospray Ionization (ESI) source was employed to determine the formulae of the
products. Nitrogen was used as the drying (8 L·min-1) and nebulizing (0.8 bar) gas at
180 °C. Scanning was performed from m/z 100 to 1000 in the standard resolution mode.
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To establish the structure of the degradation products, the reaction was carried out
using the same condition as stated above except a larger volume (300 mL) was used.
Upon completion of the reaction, the reaction mixture was extracted with either ethyl
acetate or chloroform. After removal of the solvent by rotary evaporation (0.09 MPa,
308K) the extracts were dissolved in either deuterated chloroform or methanol and
transferred to 5 mm NMR tubes. NMR experiments were carried out on a Bruker 600
MHz NMR spectrometer operating at a proton frequency of 599.73 MHz. All spectra
were recorded at 298 K using standard pulse programs from the manufacturer.
2.5 Elimination of COD and TOC
Total organic carbon (TOC) measurement was conducted on a TOC-VCPA analyzer
(Shimadzu Corp.). The feed speed was 150 ml·min-1. Chemical oxygen demand (COD)
was measured by a quick method on a Rapid Autoanalyzer (5B-1(F), Lian-hua Tech.Co.,
Ltd). A solution containing 2.5 ml sample, 0.7 ml reagent D (potassium dichromate) and
4.8 ml reagent E (catalysts) in a 20.0 ml glass tube was heated to 438K and kept for 10
min together with a blank sample and a standard sample. After 2 min of air cooling, the
heated solution was cooled by water for another 2 min. Then the absorbency of the
samples was measured at 610 nm.
2.6 Treatment of drug effluent by activated sludge
A mixed population of activated sludge microorganisms was collected from Xi'an second
sewage treatment plant (Xi’an, China). The sample of activated sludge was filtered on a
Spectra Mesh polypropylene 149-μm filter (Spectrum Laboratories Inc., Rancho
Dominguez, CA, USA) to remove aggregates. The sample was then washed three times
by centrifugation and suspended in the same volume of culture medium. To remove any
excessive amounts of dissolved organic carbon, the suspension was stirred and
maintained under oxygen at 298K for at least 24 h without exposure to the test materials.
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The volatile ratio f of activated sludge was 0.74.
90 mL of 15 µmol·L-1 drug effluent was put into the activated sludge suspension
before /after enzymatic treatment (to ensure a final drug concentration of 7.5µmol·L-1).
The samples were stirred for the duration of the study with a magnetically coupled stirrer
when air was used as the aerated gas. The sample was then left to stand for 1-2 h. The
supernatant was taken for determination of COD.
2.7 Toxicity Tests
Freshwater unicellular green alga, C. pyrenoidosa (provided by the Institute of Wuhan
Hydrobiology, Chinese Academic of Science), was cultivated in nutrient media of blue
green medium (BG11) at 298K and illuminated with cool-white fluorescent lights at a
continuous light intensity of 2000 Lx. For cell experiments, C. Pyrenoidosa was exposed,
during its log growth phase, to the toxicant at five different concentrations ( maintain final
concentration ranging from 0.01 to 0.36 mg/L) for 3-4 days at 298K. The concentration of
the alga was determined by monitoring the change of absorption at 680 nm (Ma et al.,
2006). The toxicity tests for each drug concentration were conducted in triplicate.
The growth inhibition rate i for each sample was calculated from Equation (2) and (3)
(Lange et al., 2006),

  lnODt  ln ODt  /t  t 0  (2)
0

i    c   t  /  c  100%

(3)

where t-t0 is incubation time (min); OD t 0 is absorbance at t0; ODt is absorbance at t; μ is
growth rate of all life (min-1); μc is growth rates of control culture without toxin addition
(min-1); and μt is growth rates of cultures in the presence of drugs (min-1). EC50 (drug
concentration required to cause 50% reduction in growth) values were calculated using
linear regression analysis of drug concentration as natural logarithm versus percentage
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inhibition. All correlation coefficients were > 0.99.
3. Results and discussion
3.1 Effect of reaction parameters on drug Degradation
Since various physicochemical parameters influence the degradation efficiency, it is
essential to optimize these factors in order to make the process more efficient and
practically applicable.
The pH range investigated was 2-6 due to poor stability and activity of CPO at higher
pH. Fig. S1 (A) showed that the degradation efficiency of naproxen and diclofenac
increased rapidly with increasing pH, and reached maximum around pH 3.2. The
degradation efficiency decreased sharply when pH was increased above 3.2. The
preference for such a low reaction pH has been observed for most CPO catalyzed
reactions and has been attributed to the protein’s unique active site structure and
catalytic mechanism (Liu et al., 2014; Zhang et al., 2012). CPO uses a glutamic acid
(Glu 183) as the acid-base catalyst to aid the formation of compound I (Sundaramoorthy
et al., 1995; Wang et al., 2003). The protonation of Glu183 is necessary for both the
formation of compound I and the binding of negatively charged substrates to avoid
unfavorable electrostatic interactions. Acidic environment is also needed to protonate
compound X involved in most CPO catalyzed halide dependent reactions (Chiang et al.,
1976; Dawson et al., 1988).
It is well known that high concentration of H2O2 (oxidant) inactivates most heme
containing enzymes due to internal oxidative destruction of the porphyrin prosthetic
group (Grey et al., 2007). Thus low concentrations of H2O2 are employed for reactions
catalyzed by most heme peroxidases. This strategy cannot be simply applied to CPO
because of its ability to disproportionate hydrogen peroxide. Therefore, the optimum
concentration of hydrogen peroxide needs to be determined based on the actual
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substrate. The effect of H2O2 concentration on CPO catalyzed degradation of diclofenac
and naproxen is shown in Fig. S1B. As expected for all peroxidases, no degradation of
either drug was observed before the addition of H2O2. The degradation efficiency of both
drugs increased as H2O2 concentration is increased. Maximum rate is achieved when
total H2O2 concentration reached 0.1 mmol·L-1. Further addition of H2O2, however,
repressed the degradation of both drugs possibly due to formation of compound III
caused by high concentrations of H2O2 (Ayala et al., 2011). Therefore, 0.1 mmol·L-1 of
H2O2 was chosen in the degradation of both diclofenac and naproxen in all subsequent
experiments.
Optimizing CPO concentration not only improves degradation efficiency but also saves
cost of operation. The range of CPO concentration tested was 0.25-6.0 nmol·L-1 for
diclofenac and 1-23.0 nmol·L-1 for naproxen. Fig. S1 (C) showed that degradation
efficiency of both drugs increased rapidly as CPO concentration was increased.
Complete degradation of the drugs was achieved when CPO concentration was above
5.0 nmol·L-1 for diclofenac, and 20.0 nmol·L-1 for naproxen, indicating that CPO is
extremely efficient in the degradation of the subject drugs.
It is remarkable to note that CPO degrades both diclofenac and naproxen with a
remarkable rate. As shown in Fig. S1 (D), about 70% of diclofenac and 75% of naproxen
is degraded within 1 min. The complete degradation was achieved in only 9 and 7 min
for diclofenac and naproxen, respectively, at optimum reaction condition.
3.2 Determination of products by HPLC-MS and NMR
Tremendous efforts have been made to characterize the intermediates and final
products generated from diclofenac and naproxen degradation (Faber et al., 2012; Urrea
et al., 2010). Plausible mechanisms have been proposed for both drugs based on the
intermediates and final products identified from different processes. To understand the
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mechanisms of CPO catalyzed degradation and to evaluate the potential of this
enzymatic method in environmental and industrial applications, both HPLC-MS and
NMR analyses are employed to establish the structures of the putative products from the
two drugs.
The hydroxylation of aromatic rings and O-demethylation of esters have been reported
for several unspecific peroxygenase (UPOs) (Hofrichter et al., 2014; Kinne et al., 2009;
Piontek et al., 2013; Poraj-Kobielska et al., 2011; Wang et al., 2013), a class of hemethiolate proteins related to CPO and cytochromes P450. However, these two activities
have not been reported for CPO. In this work, CPO catalyzed hydroxylation of diclofenac
and O-demethylation of naproxen were observed. The degradation of both diclofenac
and naproxen was confirmed by HPLC analysis of the reaction product as shown in Fig.
2. The MS spectra of samples from diclofenac degradation (Fig.2) suggested the
formation of six putative products. The peak that eluted at 2.6 min (Fig.2A) shows a
molecular ion [M-H]- at m/z 311, indicating the addition of an oxygen atom to the parent
compound. Multiple possibilities exist as oxygen can be added at all possible positions of
the two benzene rings. However, NMR analysis (Fig.3) suggested compound [II] as the
major product corresponding to this molecular ion. Since the coupling pattern of the
chloride bearing ring remained in the product, the oxygen must have been added to the
acetate bearing ring with oxygen added at the para-carbon of the imino group. The NOE
between peak “a” at 3.77 ppm (singlet, 2H) and peak “b” at 7.25 ppm (Fig.S3), the
COSY correlation and splitting pattern confirm the structure of compound [II] as reported
previously (Blum et al., 1996; Calza et al., 2006; Coelho et al., 2009; Osorio et al., 2014;
Sparidans et al., 2008). Product [I], 4’-hydroxydiclofenac, is commercially available and
displays a quite different NMR spectral pattern as shown in Fig. S4 and Fig. S5). The
peak eluted at 3.1 min (Fig.2B) displayed a molecular ion [M-H]- at m/z 328, indicating
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the addition of two oxygen atoms to the parent compound or the addition of one oxygen
atom to compound [II]. This product also showed a major fragmentation ion at m/z 284
(Fig.2B), assignable to the decarboxylation of the major product. Decarboxylation was
also observed for diclofenac itself (Fig.S6). The NMR spectrum (Fig.S7) of this product
showed the absence of a three proton coupling pattern in the aromatic region as
displayed by both the parent compound and compound [II], suggesting the oxygen atom
is added to the chloride bearing ring as shown in compound IV. This is in good
agreement with observations made with other methods (Blum et al., 1996; Calza et al.,
2006; Osorio et al., 2014). The peak eluted at 2.7 min showed a molecular ion [M-H]- at
m/z 325 (Fig.2C), assignable to compound [V] or [VI] due to further oxidation of product
[II] or [IV]. However, neither compound V nor VI was detected in NMR experiments,
implicating that these products might form only in the ionization process within mass
spectrometer.
Based on the products identified from our LC-MS and NMR analysis, the sequence of
diclofenac degradation catalyzed by CPO is proposed (Fig.4). The diverse catalytic
activity of CPO makes it possible to produce a broad array of products from diclofenac
degradation, however, under the conditions employed in our study, only hydroxylation
activity is observed. This can be appreciated by the similarity between CPO and
cytochromes P450 that metabolize most xenobiotics via hydroxylation. Thus CPO
converts diclofenac to either monohydroxylated or dihydroxylated products, the same as
the major products observed in the metabolism of diclofenac (Blum et al., 1996; Osorio
et al., 2014). The close similarity among possible hydroxylation products makes it difficult
to isolate and purify individual product. This drawback does not comprise the aim of this
study.
The identification of products from CPO catalyzed degradation of naproxen is
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achieved by detailed NMR analysis of the products with the aid of MS. The most
noticeable difference between proton NMR spectra of the products and the parent drug,
naproxen, is the absence of the methoxy signal (peak “i” around 3.9 ppm, Fig.S8 and
S9) in the products as shown in Fig.5. This suggests the demethylation of naproxen as
reported previously (Sidelmann et al., 2001; Urrea et al., 2010). Although CPO catalyzed
N-demethylation has been reported (Kedderis et al., 1980), the observed Odemethylation represents a novel activity of CPO. This is reminiscent of the activity
displayed by P450 (Meunier et al., 2004) and UPOs (Hofrichter et al., 2014; Kinne et al.,
2009) that are structurally related to CPO. The methyl (peak “a” at 1.53 ppm, doublet,
J=6.56, 3H) and the methine (peak “b” at 4.99 ppm, quartets, J=6.56, 1H) signals from
the product are indicative of the propionic acid part of naproxen. These signals are
downfield shifted compared to the corresponding signals in the parent drug molecule,
consistent with observations reported previously(Sidelmann et al., 2001; Urrea et al.,
2010). Both the methyl and the methine signals displayed NOE to a peak at 7.42 ppm
(peak “h”, doublet, J=1.18, 1H) and a peak at 7.48 ppm (signal “c”, doublet of doublet,
J=8.03 and 1.18, 1H) as shown in Fig.5 (A). The peak at 7.48 ppm is strongly coupled to
a peak at 8.09 ppm (resonance “d”, doublet, J=8.03, 1H) as shown in Fig.5 (B). The
NOE and coupling pattern of this product suggests no modification occurred to the
propionic group bearing ring of naproxen during degradation. The remaining aromatic
signals, peak “g” at 7.44 ppm (doublet, J=10.11, 1H) and peak “f” at 6.44 ppm (doublet,
J=10.18, 1H) are strongly coupled (Fig.5 (B)), demonstrating their vicinal relationship.
Based on the above NMR spectral property, this product is proposed to be 2-(5,6dihydroxynaphthalen-2-yl)propanoic acid due to modification at 5-C of naproxen.
However, the NMR spectra of commercially available desmethylnaproxen (Fig. S10 and
Fig. S11) do not support the proposed structure of this degradation product.
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Furthermore, the MS of this product shows a molecular ion [M-H]- at m/z 311, also
inconsistent with the structure proposed (expected m/z at 231). The difference of a mass
of 80 between the expected and the observed mass, suggests the phosphorylation of
one of the hydroxyl groups. Esterification of desmethylnaproxen has been reported
previously (Sidelmann et al., 2001). The high phosphate concentration and the
extremely low pH used in our degradation study make it feasible to phosphorylate 2-(5,6dihydroxynaphthalen-2-yl)propanoic acid and give product (I) as shown in Figure 6.
Product (I) can be further degraded to 2-(5,8-dihydroxy-6-(phosphonooxy)naphthalen-2yl)propanoic acid via hydroxylation at the 8-C. However, this product is not observed in
either NMR or MS experiments. The observation of a molecular ion [M-H]- at m/z 325
suggests the formation of product (II) as shown in Fig.6.
Based on the major products identified from our study, the reaction sequence of
naproxen degradation catalyzed by CPO is proposed (Fig.7). Similar as the degradation
of diclofenac, CPO catalyzed degradation of naproxen is achieved primarily via CPO’s
monooxygenase activity. Thus CPO degrades naproxen to either monohydroxylated or
dihydroxylated products, similar as the major products observed in bacterial degradation
of naproxen (Wojcieszyńska et al., 2014). Initially, naproxen was degraded to
desmethylnaproxen (Aresta et al., 2006; Urrea et al., 2010). The desmethylnaproxen is
then phosphorylated to [(2-(6-(phosphonooxy)naphthalen-2-yl)acetic acid [a], not
observed)] in the presence of high concentrations of phosphate and under low pH
condition employed. Esterification of desmethylnaproxen has been reported in the
literature (Sidelmann et al., 2001). Next, [a] was hydroxylated to 2-(5-hydroxy-6(phosphonooxy)naphthalen-2-yl)propanoic acid [I] corresponding to m/z 311 observed in
Figure 6. Product (I) was then degraded to 2-(5,8-dihydroxy-6(phosphonooxy)naphthalen-2-yl)propanoic acid [b, expected m/z=327] which is instantly
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oxidized to 2-(5,8-dioxo-6-(phosphonooxy)-5,8-dihydronaphthalen-2-yl)propanoic acid
(II, m/z=325) as shown in Fig.6.
The products identified in our NMR and MS analysis are subjected to further oxidative
transformation as supported by the results from activated sludge experiment as well as
eco-toxicity test.
3.3 Reduction in chemical oxygen demand (COD) and total organic carbon (TOC)
Table 1 showed that only 4.9% , 9.1% of COD and 25%, 7.6% of TOC removal was
achieved for diclofenac and naproxen, respectively. It is therefore proposed that CPO
catalyzed degradation can serve as an efficient pre-treatment step in waste water
treatment. This can be combined with subsequent bioremediation technologies
(activated sludge) for complete decontamination of the two drugs in waste water.
3.4 Combined treatment of drug effluent by enzymatic oxidation and activated sludge
As indicated in Table 1, the COD value of drug effluent did not decrease noticeably
after CPO-treatment. However, compared with the parent drugs, the products from CPO
catalyzed degradation have improved solubility in aqueous media and are more
vulnerable to further biodegradation. This conclusion was confirmed by the observation
that treatment of CPO-catalyzed reaction mixture with activated sludge increased COD
removal from 4.9% and 9.1% to 85% and 86% for diclofenac and naproxen, respectively.
On the other hand, treatment by activated sludge alone only removes 49% and 54%, of
the COD for diclofenac and naproxen, respectively, suggesting that more effective
decontamination of the two drugs can be achieved through CPO pre-treatment followed
by existing bioremediation technologies (activated sludge).
3.5 Evaluation of the eco-toxicity of the products
In some cases simple destruction of a drug is inadequate, since the resulting products
may also be highly toxic, and special attention must therefore be paid to toxicity
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assessment of products to ensure that the agent has been effectively detoxified.
However, toxicity evaluation about the products from diclofenac and naproxen are not
readily available. Biological assays offer a direct measure to evaluate the magnitude of
the potential health risk of chemicals. Therefore, a growth-inhibitory test was carried out
using C. Pyrenoidosa.
Fig.S10 showed that the 72-h EC50 increased with the increase in degradation
efficiency. The value was 0.25 mg·L-1 for diclofenac and 0.33 mg·L-1 for naproxen at the
end of degradation. These results demonstrated that the products had lower toxicity
compared with the parent drugs, suggesting the great potential of using CPO as an
efficient catalyst in the safe removal of these drugs from environmental.
4. Conclusion
In summary, our study demonstrated that CPO catalyzed oxidative degradation is a
promising alternative for treatment of waste water containing non-steroidal antiinflammatory drugs. Complete degradation of diclofenac and naproxen is reached in only
9 and 7 min, respectively, under mild conditions.

The products identified by HPLC-MS suggested the initial hydroxylation of the drug
molecules followed by further oxidative transformation. The biodegradability of the
decomposition products was significantly increased as confirmed by COD measurement
after combining the enzymatic oxidation with activated sludge treatment. Most
significantly, the products of both diclofenac and naproxen had dramatically lower
toxicity than the original drugs as judged by the 72-h EC50 value of C. Pyrenoidos. Our
results demonstrates that CPO can serve as an efficient, cost-effective, and
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environmentally friendly catalyst for large-scale treatment of waste water contaminated
with the two drugs studied in this work..
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Figure captions:
Fig. 1 Chemical structures of diclofenac (a) and naproxen (b)
Fig. 2 ESI-ion trap mass spectra of the degradation products from CPO catalyzed
oxidation of diclofenac recorded in negative mode.
Fig. 3 COSY of diclofenac product [II] in chloroform-d.
Fig. 4 Proposed degradation pathway of diclofenac during CPO-catalytic oxidative
process.
Fig. 5 Proton NMR (A) NOESY and (B) COSY spectra of naproxen product [I]. The week
NOEs between peaks “a” and “c” and between peaks “b” and “c” can only be
observed at lower contour levels. The NOE and coupling patterns unequivocally
define the structure of this degradation product.
Fig. 6 ESI-ion trap mass spectra of the degradation products from CPO catalyzed
oxidation of naproxen recorded in negative mode.
Fig. 7 Proposed degradation pathway of naproxen during CPO-catalytic oxidative
process.

Table 1 Elimination of COD and TOC by CPO catalyzed oxidative degradation.
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Fig. 1 Chemical structures of diclofenac (a) and naproxen (b)
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Fig. 2 ESI-ion trap mass spectra of the degradation products from CPO catalyzed
oxidation of diclofenac recorded in negative mode.
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Fig. 3 COSY of diclofenac product [II] in chloroform-d.
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Fig. 4 Proposed degradation pathway of diclofenac during CPO-catalytic oxidative
process.
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(A)

(B)

Fig. 5 Proton NMR (A) NOESY and (B) COSY spectra of naproxen product [I]. The week
NOEs between peaks “a” and “c” and between peaks “b” and “c” can only be
observed at lower contour levels. The NOE and coupling patterns unequivocally
define the structure of this degradation product.
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Fig. 6 ESI-ion trap mass spectra of the degradation products from CPO catalyzed
oxidation of naproxen recorded in negative mode.
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Fig. 7 Proposed degradation pathway of naproxen during CPO-catalytic oxidative
process
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Table 1 Elimination of COD and TOC by CPO catalyzed oxidative degradation

COD

COD removal

TOC

TOC removal

(mg ·L-1)

(%)

(mg ·L-1)

(%)

diclofenac

41→39

4.9

8.3→6.2

25

naproxen

22→20

9.1

158→146

7.6

substance
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Supporting Information
Fig. S1 The relationship between degradation efficiency and reaction condition of CPO
catalyzed degradation of diclofenac (left) and naproxen (right).
(A)

(B)

(C)

(D)
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Fig. S2 The HPLC elution profile of degradation solution both of diclofenac and naproxen
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Fig. S3 NOESY of diclofenac product [II]
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Fig. S4. COSY of authentic 4’-hydroxydiclofenac purchased from Sigma Aldrich
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Fig. S5. NOESY of authentic 4’-hydroxydiclofenac purchased from Sigma Aldrich
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Fig. S6. MS of diclofenac
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Fig. S7. COSY of diclofenac product [IV]
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Fig. S8. COSY of naproxen
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Fig. S9. NOESY of naproxen
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Fig. S10. COSY of authentic desmethylnaproxen purchased from Sigma Aldrich
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Fig. S11. NOESY of authentic desmethylnaproxen purchased from Sigma Aldrich

135

Fig. S12. Dependence of EC50 value on degradation efficiency of diclofenac (A) and
naproxen (B). (Green algae (OD t0=0.05) and final substrate concentration
range 0.15-0.36 mg·L-1)
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Figure A1.1 Mass Spectrums of APAP and its metabolites
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C15H13NO2 (CM7)

Figure A1.2 The mass spectra of CBZ and its metabolites.
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Figure A1.2 (cont.) The mass spectra of CBZ and its metabolites.
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Figure A1.3 The mass spectra of SMZ and its metabolites.
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Figure A1.3 (cont.) The mass spectra of SMZ and its metabolites.

151

152

153

154

155

156

157

158

159

160

161

162

Figure A3.1 DNA sequence of full-length wide type CPO gene.
ATGTTCTCCAAGGTCCTTCCCTTCGTGGGAGCGGTTGCCGCCCTCCCTCACTC
CGTCCGTCAGGAGCCTGGCTCCGGCATTGGCTACCCATACGACAACAACACC
CTGCCATATGTCGCCCCAGGTCCTACCGACTCTCGTGCTCCTTGCCCAGCTCT
GAACGCTCTTGCCAACCACGGTTACATTCCTCACGATGGCCGTGCCATCAGC
AGGGAGACCCTCCAGAACGCTTTCCTCAACCACATGGGTATTGCCAACTCCG
TCATTGAGCTTGCTCTGACCAACGCCTTCGTCGTCTGCGAGTACGTTACTGGC
TCCGACTGTGGTGACAGCCTTGTCAACCTGACTCTGCTCGCCGAGCCCCACGC
TTTCGAGCACGACCACTCCTTCTCCCGCAAGGATTACAAGCAGGGTGTCGCC
AACTCCAACGACTTCATCGACAAC AGGAACTTCGATGCCGAGACCTTCCAGA
CCTCTCTGGATGTCGTTGCAGGCAAGACCCACTTCGACTATGCCGACATGAA
CGAGATCCGCCTTCAGCGCGAGTCCCTCTCCAACGAGCTTGACTTCCCCGGTT
GGTTCACCGAGTCCAAGCCAATCCAGAACGTCGAGTCTGGCTTCATCTTCGCC
CTTGTCTCTGACTTCAACCTGCCCGACAACGATGAGAACCCTCTGGTTCGCAT
TGACTGGTGGAAGTACTGGTTCACCAACGAGTCCTTCCCATACCACCTCGGCT
GGCACCCCCCGTCTCCAGCCAGGGAGATCGAGTTCGTCACCTCCGCCTCCTCC
GCTGTCCTGGCTGCCTCTGTCACCTCTACTCCATCTTCCCTTCCATCCGGTGCC
ATCGGCCCAGGTGCCGAGGCTGTCCCTCTCTCCTTCGCCTCCACCATGACCCC
ATTCCTCCTCGCCACCAATGCTCCTTACTACGCCCAGGACCCAACTCTCGGCC
CCAACGACAAGCGTGAGGCTGCCCCAGCTGCCACCACCTCCATGGCCGTCTT
CAAGAACCCAT ACCTCGAGGCCATT GGC ACCCAGGACATC AAGAACCA GCA
GGCTTACGTCAGCTCCAAGGCTGCTGCCATGGCCTCTGCCATGGCCGCCAAC
AAGGCCCGCAACCTTTAA
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Figure A3.2 Amino acid sequence of full-length of wide type CPO.
1

XEPGSGIGYP YDNNTLPYVA PGPTDSRAPC PALNALANHG YIPHDGRAIS

51

RETLQNAFLN HMGIANSVIE LALTNAFVVC EYVTGSDCGD SLVNLTLLAE

101 PHAFEHDHSF SRKDYKQGVA NSNDFIDNRN FDAETFQTSL DVVAGKTHFD
151 YADMNEIRLQ RESLSNELDF PGWFTESKPI QNVESGFIFA LVSDFNLPDN
201 DENPLVRIDW WKYWFTNESF PYHLGWHPPS PAREIEFVTS ASSAVLAASV
251 TSTPSSLPSG AIGPGAEAVP LSFASTMTPF LLATNAPYYA QDPTLGPND

164

VITA

QINGHAO HE

Dec 07, 1988

Born, Nanjing, China

2007-2011

Bachelor of Management, Nanjing
University of Chinese Medicine

2011-

Doctoral Candidate in Chemistry
Florida international University

PUBILICATIONS
Rui Zhang, Qinghao He, David Chatfield, and Xiaotang Wang “Paramagnetic
nuclear magnetic resonance relaxation and molecular mechanics studies of the
chloroperoxidase–indole complex: insights into the mechanism of
chloroperoxidase-catalyzed regioselective oxidation of indole”. Biochemistry,
2013. 52(21): p. 3688-3701.

Rui Zhang , Qinghao He, Yi Huang and Xiaotang Wang “Spectroscopic and

QM/MM investigations of Chloroperoxidase catalyzed degradation of
orange G” Archives of Biochemistry and Biophysics, 2016. 596 P. 1-9

165

